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Abstract
As thrombosis proceeds, platelets in a clot can expose phosphatidylserine (PS), providing a negatively
charged surface for thrombin generation. These PS+ platelets have been shown to sort to the perimeter
of platelet masses via platelet contraction. However, it remains unclear how thrombin and fibrin affect
PS+ platelet sorting within a clot. We used an 8-channel microfluidic device to perfuse blood over
collagen/TF to evaluate temporal and spatial PS+ platelet sorting. We found that thrombin inhibition, fibrin
polymerization inhibition, or fibrinolysis each increased clot contraction and PS sorting. Fibrin attenuated
clot contraction and PS sorting. Clots without fibrin had a 3.6-times greater contraction than clots with
fibrin. Based on these results, we wanted to study contraction further. We tested the effect of inhibitors of
ADP and/or thromboxane A2 (TXA2) signaling on clot contraction. We developed two automated imaging
methods to score fluorescent platelet percent contraction: (1) “global” measurement of clot length, and
(2) “local” changes in surface area coverage of platelet aggregates within the clot. Total platelet
fluorescence and global aggregate contraction were highly correlated (R2 =0.87). Local aggregate
contraction was more pronounced than global aggregate contraction across all inhibition conditions.
Conditions with TXA2 inhibition were shown to significantly reduce local aggregate contraction relative to
conditions without TXA2, unlike conditions with ADP inhibition. Lastly, we recently obtained a glycoprotein
VI (GPVI) inhibitor. GPVI is a collagen receptor on platelets that drives platelet activation; however, its role
at later stages in clotting remains unclear. We tested the effect of anti-GPVI Fab on PS exposure, which
occurs at later stages of platelet activation. On collagen/TF, Fab present at t=0s reduced PS exposure, but
had no effect when added 30 or 90 seconds later. Thrombin generated via PS exposure had an important
role in driving platelet deposition when Fab was present, since inhibition of PS via annexin V binding in the
presence of Fab significantly inhibited platelet deposition. Our results from these studies help elucidate
the relationship between platelet activation, PS exposure, fibrin, and clot contraction.
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ABSTRACT
UNDERSTANDING THE RELATIONSHIP BETWEEN CLOT CONTRACTION AND
PLATELET BIOLOGY UNDER HEMODYNAMIC CONDITIONS
Kevin Timothy Trigani
Scott L. Diamond

As thrombosis proceeds, platelets in a clot can expose phosphatidylserine (PS),
providing a negatively charged surface for thrombin generation. These PS+ platelets have
been shown to sort to the perimeter of platelet masses via platelet contraction. However,
it remains unclear how thrombin and fibrin affect PS+ platelet sorting within a clot. We
used an 8-channel microfluidic device to perfuse blood over collagen/TF to evaluate
temporal and spatial PS+ platelet sorting. We found that thrombin inhibition, fibrin
polymerization inhibition, or fibrinolysis each increased clot contraction and PS sorting.
Fibrin attenuated clot contraction and PS sorting. Clots without fibrin had a 3.6-times
greater contraction than clots with fibrin. Based on these results, we wanted to study
contraction further. We tested the effect of inhibitors of ADP and/or thromboxane A2
(TXA2) signaling on clot contraction. We developed two automated imaging methods to
score fluorescent platelet percent contraction: (1) “global” measurement of clot length,
and (2) “local” changes in surface area coverage of platelet aggregates within the clot.
Total platelet fluorescence and global aggregate contraction were highly correlated (R2
=0.87). Local aggregate contraction was more pronounced than global aggregate
contraction across all inhibition conditions. Conditions with TXA2 inhibition were shown
to significantly reduce local aggregate contraction relative to conditions without TXA2,
iv

unlike conditions with ADP inhibition. Lastly, we recently obtained a glycoprotein VI
(GPVI) inhibitor. GPVI is a collagen receptor on platelets that drives platelet activation;
however, its role at later stages in clotting remains unclear. We tested the effect of antiGPVI Fab on PS exposure, which occurs at later stages of platelet activation. On
collagen/TF, Fab present at t=0s reduced PS exposure, but had no effect when added 30
or 90 seconds later. Thrombin generated via PS exposure had an important role in driving
platelet deposition when Fab was present, since inhibition of PS via annexin V binding in
the presence of Fab significantly inhibited platelet deposition. Our results from these
studies help elucidate the relationship between platelet activation, PS exposure, fibrin,
and clot contraction.

v

TABLE OF CONTENTS
ACKNOWLEDGMENTS ............................................................................................ iii
ABSTRACT.................................................................................................................. iv
TABLE OF CONTENTS ............................................................................................. vi
LIST OF FIGURES ................................................................................................... viii
CHAPTER 1: INTRODUCTION ................................................................................. 1
1.1

Hemostasis and Thrombosis ...................................................................................................... 1

1.2

Clot Contraction......................................................................................................................... 2

1.3

Phosphatidylserine Exposure ..................................................................................................... 2

1.4

Microfluidics .............................................................................................................................. 3

CHAPTER 2: FIBRIN ATTENUATES PHOSPHATIDYLSERINE SORTING ...... 4
2.1

Introduction ............................................................................................................................... 4

2.2

Materials and Methods .............................................................................................................. 7

2.3

Results ...................................................................................................................................... 10

2.4

Discussion ................................................................................................................................. 24

CHAPTER 3: THE ROLE OF ADP AND TXA2 IN LIMITING CONTRACTION
..................................................................................................................................... 29
3.1

Introduction ............................................................................................................................. 29

3.2

Materials and Methods ............................................................................................................ 32

3.3

Results ...................................................................................................................................... 37

3.4

Discussion ................................................................................................................................. 46

CHAPTER 4: THE EFFECT OF ANTI-GPVI FAB E12 ON PLATELET
DEPOSITION AND PHOSPHATIDYLSERINE EXPOSURE ................................ 51
vi

4.1

Introduction ............................................................................................................................. 51

4.2

Materials and Methods ............................................................................................................ 54

4.3

Results ...................................................................................................................................... 58

4.4

Discussion ................................................................................................................................. 70

CHAPTER 5: FUTURE WORK ................................................................................ 74
5.1

Further investigation of PS+ platelet sorting in clot development ........................................... 74

5.2

Evaluating the effects of secondary platelet inhibition on clot contraction ............................. 77

5.3
Further evaluation of anti-GPVI Fab E12 and the role of PS exposure in propagating platelet
deposition .............................................................................................................................................. 79

APPENDICES ............................................................................................................. 87
Appendix A: Chapter 2......................................................................................................................... 87
Appendix B: Chapter 3 ......................................................................................................................... 99
Appendix C: Chapter 4....................................................................................................................... 102

BIBLIOGRAPHY ..................................................................................................... 107

vii

LIST OF FIGURES
Figure 2-1. Inhibition of thrombin enhances PS sorting. ................................................ 11
Figure 2-2. Inhibition of fibrin polymerization enhances PS exposure and sorting. ........ 13
Figure 2-3. Fibrinolysis enhances PS sorting. ................................................................ 15
Figure 2-4. PS sorting is enhanced in the absence of procoagulant conditions (no TF). .. 17
Figure 2-5. PS sorting correlates with contraction, and correlates inversely with fibrin FI.
..................................................................................................................................... 19
Figure 2-6. Extent of PS sorting and % contraction is consistent across similar fibrin
conditions. .................................................................................................................... 20
Figure 2-7. Pearson correlation coefficient measures PS temporal sorting and
autocorrelation metric measures PS spatial sorting. ....................................................... 22
Figure 3-1. ASA, 2-MeSAMP, and MRS-2179 have an additive effect on limiting platelet
deposition, but do not have an additive effect on limiting P-selectin display. ................. 37
Figure 3-2. Quantitative fluorescence data from Figure 3-1. .......................................... 38
Figure 3-3. P-selectin+ platelets have limited global and local contraction; ASA, 2MeSAMP, and MRS-2179 have a limiting effect on global platelet contraction, while
only ASA limits local platelet contraction. .................................................................... 40
Figure 3-4. Platelet fluorescence correlates with global contraction. .............................. 43
Figure 3-5. ASA limits local platelet contraction, while 2-MeSAMP and MRS-2179 have
no effect. ....................................................................................................................... 45
Figure 3-6. Schematic of clot development and contractile processes under control
conditions (A) and with ADP/TXA2 inhibitors present (B). .......................................... 46
Figure 4-1. Inhibition of GPVI shows significant decrease in PS exposure. ................... 58
Figure 4-2. Decrease in annexin V in the presence of anti-GPVI is due from anti-GPVI,
not limited platelet deposition or fibrin polymerization.................................................. 60
Figure 4-3. Effects of anti-GPVI Fab require its presence from the initiation of clot
development in the presence of thrombin. ..................................................................... 62
Figure 4-4. Effects of anti-GPVI Fab on clot development are reversible....................... 64
Figure 4-5. Annexin V and anti-GPVI Fab have additive effect on limiting platelet
deposition. .................................................................................................................... 67
viii

Figure 4-6. Representative 3D images of clot end point. ................................................ 69
Figure 5-1. Pearson correlation coefficients of annexin V fluorescence between final clot
image (at 15 minutes) and clot image at varying time points among all conditions tested.
..................................................................................................................................... 75
Figure 5-2. Time-sequential inhibition of thrombin demonstrated varying anti-GPVI
potency on platelet deposition and fibrin deposition. ..................................................... 79
Figure 5-3. Time-sequential addition of annexin V in the presence of anti-GPVI had little
effect on platelet deposition or PS exposure, but a minimal effect on fibrin deposition. . 83
Figure 5-4. Annexin V has a slight inhibitory effect on fibrin deposition. ...................... 85

ix

CHAPTER 1: INTRODUCTION

1.1

Hemostasis and Thrombosis
When a blood vessel in the body is disrupted, hemostasis occurs to prevent blood

loss. Hemostasis involves a number of elements, including platelets, fibrin, fibrinogen,
von Willebrand factor (vWF), and thrombin, among others. Collagen becomes exposed
when the endothelial layer of a vessel is disrupted. This initial collagen exposure triggers
platelets in a nascent state to become activated near the site of injury, where they can
begin to bind. As platelets bind to collagen, they can send signals to other nearby
platelets to begin to activate and bind as well, causing a platelet plug to form.
As platelets become activated and aggregate, coagulation also begins to occur.
Coagulation is the process by which fibrin forms. There are two pathways by which
fibrin can form: (1) intrinsic/contact activation pathway, or (2) extrinsic/tissue factor
pathway. With intrinsic pathway coagulation, Factor XII can be activated through contact
with a variety of different negatively charged surfaces or molecules, which leads to a
cascade of reactions that results in the conversion of prothrombin to thrombin. Upon
thrombin formation, soluble fibrinogen is converted to insoluble fibrin, which then
becomes cross-linked to form polymerized fibrin. Another pathway exists to form fibrin,
whereby exposure to tissue factor (TF) leads to activation of Factor X, which converts
prothrombin to thrombin, eventually leading to fibrin polymerization. Together, platelets
and fibrin limit blood loss from a disrupted or injured vessel.
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Under normal conditions, hemostasis allows for the correct balance of procoagulant and anti-coagulant forces. This balance allows for blood loss to be limited
when a blood vessel is injured or disrupted; it also helps to prevent unwanted or
excessive blood clotting. When hemostasis is no longer maintained due from excessive
pro-coagulant forces, thrombosis occurs. Thrombosis leads to increased clot embolization
and vessel occlusion, which can result in a number of clinical complications, including
myocardial infarction or ischemic stroke. Gaining a deeper understanding of this delicate
balance in blood clotting is important to better treat different complex clinical conditions.
1.2

Clot Contraction
In the final stages of hemostasis, aggregated platelets and polymerized fibrin in

the clot begin to contract. The process of clot contraction is quite complex and involves a
number of components within the blood clot: platelets, fibrinogen, fibrin, red blood cells
(RBCs), vWF, among others. Contraction reduces the physical space and gaps within a
blood clot, preventing blood loss and allowing for the restoration of blood flow [1–5].
Contraction ultimately leads to clot resolution, which ensures that normal blood flow is
restored in the vessel. In cases where contraction is limited or does not occur properly,
there can be an increased risk of bleeding [6].
1.3

Phosphatidylserine Exposure
When platelets bind to collagen, they begin to activate and change in a number of

different ways: physical shape change, integrin activation, granule secretion, and
exposure of phospholipids [7]. One such phospholipid that can be exposed upon platelet
2

activation is phosphatidylserine (PS). At rest, PS is normally found on the inside of the
platelet membrane, but upon activation, PS can be exposed to the outer membrane
surface [8]. An enzyme called TMEM16F facilitates the externalization of PS, where it
provides a negatively charged surface for tenase and prothrombinase complexes to
assemble to assist in the formation of Factor X and thrombin, respectively [9]. When
there is a mutation in TMEM16F, a condition called Scott Syndrome can occur, which
can lead to mild bleeding [9–11].
1.4

Microfluidics
Blood clotting is often studied under static conditions, and studies can use an

altered blood composition (e.g. platelet-rich plasma, platelet-poor plasma, etc.) to
evaluate hemostatic or thrombotic behavior. While these studies can be insightful, they
do not seek to mimic conditions present in the body; and while in vivo mice experiments
can provide useful insight into the in vivo dynamics of blood clotting, mouse blood
clotting components are not identical to human clotting components [12]. Our lab has
designed an 8-channel microfluidic device that can evaluate 8 independent conditions in
human whole blood clotting under shear flow [13,14]. We can control for extrinsic or
intrinsic coagulation by patterning collagen ± TF . We can run experiments at a wide
range of shear rates, including arterial or venous shear rates. Fluorophores can be added
to blood to study different components (e.g. platelets, fibrin, P-selectin, etc.), where we
use epifluorescence microscopy to record images at different time points throughout the
experiment.
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CHAPTER 2: FIBRIN ATTENUATES PHOSPHATIDYLSERINE SORTING

2.1

Introduction
Platelet adhesion and deposition are primary hemostatic events that allow

engagement of the coagulation cascade (secondary hemostasis). Upon adhering to
collagen, platelet activation via GPVI signaling drives ADP release, thromboxane
synthesis, and integrin αIIbβ3 activation. Tissue factor (TF) can drive thrombin and fibrin
generation via the extrinsic pathway, which is propagated by coagulation factors that are
bound to phosphatidylserine-positive (PS+) platelets [15]. Continued clot growth requires
fibrinogen-αIIbβ3 cross bridging of platelets.
Platelets in clots can display heterogeneous traits during clot development, as
detected by P-selectin display in the core/shell model of hemostasis [16–18]. PS exposure
is also a differentiating factor between platelet subpopulations [17]. In procoagulant
platelets experiencing sustained calcium mobilization, PS is externalized from the inner
leaflet of the platelet membrane to the outer leaflet via scramblases. PS provides a surface
for thrombin generation that is supportive of thrombosis [19,20]. PS+ platelets have been
shown to exhibit ballooning and procoagulant spreading [21], as well as colocalization of
coagulation factors that promote a rapid increase in thrombin formation [22,23].
Once platelets are activated, enzymes like TMEM16F induce the externalization
of PS from the inner leaflet to the outer leaflet of the platelet membrane [9].
Externalization of PS is significantly decreased in Scott syndrome patients, as a result of
a mutation in TMEM16F [9–11]. Patients with Scott syndrome experience a mild
4

bleeding phenotype, which points to the importance of PS exposure in helping to
facilitate coagulation. Baig, et al. [10] used a TMEM16F knockout mouse model to show
that TMEM16F is critical for PS exposure, although residual PS on knockout platelets
suggested there may be other mechanisms for PS exposure. Activated platelets are less
efficient at externalizing PS under static conditions, suggesting shear forces play an
important role in PS exposure [19,24]. PS-exposing platelets display low levels of αIIbβ3
in the activated conformation [25]. Upon initial stimulation by GPVI, αIIbβ3 is activated in
platelets, but only PS-exposing platelets display pronounced inactivation of αIIbβ3 [25–
27].
Understanding the distribution of PS on platelets in a growing thrombus has been
a subject of several studies. Munnix, et al. [27] first demonstrated a ring of PS+ platelets
at the base of a platelet deposit. They found human blood perfused at 1000 s-1 over
collagen in the presence of TF/CaCl2 resulted in a heterogeneous distribution of annexin
V around the periphery of CD61+ platelets from the initial phases of thrombus formation,
although it remained unclear the mechanism for this ring-like structure. To elucidate this
phenomenon, Nechipurenko, et al. [28] showed that procoagulant platelets, rich in PS,
formed a ring-like structure around contracted thrombi and often colocalized with fibrin.
They used non-muscle myosin-deficient mouse blood to show that when contraction is
inhibited, a ring of PS+ platelets does not form around the platelet mass, concluding that
contraction drives PS+ platelets to the periphery of clots.
Although fibrin contributes to contraction through its interaction with platelets,
fibrin’s physical limitation on contraction has been supported by recent in vitro and in
5

vivo studies. Chen, et al. [29] developed a microfluidic system to evaluate dynamics of
thrombus formation under shear flow. One of their findings was that while fibrin
contributes to clot formation and stabilization, clot contraction is due primarily from
contractile forces generated by activated platelets and transmitted between platelets and
collagen. Samson, et al. [30] found that blocking endogenous fibrinolysis in vivo reduced
clot contraction. In their model, fibrin contributes to clot rigidity; fibrinolysis decreases
the amount of fibrin polymers and thus decreases rigidity, resulting in enhanced clot
contraction.
Here, we investigated how inhibition of the coagulation cascade in several
different conditions alters PS exposure and distribution in clot formation. We used a
microfluidic device to perfuse whole blood (WB) at physiological shear rates to evaluate
PS distribution during clot development. In this assay, we refer to a clot as the entire area
covered by the collagen strip, which subsequently includes numerous platelet masses.
Temporal and spatial sorting of PS+ platelets were evaluated using a Pearson correlation
coefficient and an autocorrelation metric, respectively. We found that the absence of
fibrin within a clot enhanced PS+ platelet sorting (also referred to as PS sorting) to the
periphery of platelet masses. Conversely, the presence of fibrin attenuated PS sorting, as
the PS distribution within the clot was more homogeneous by comparison. These findings
demonstrate that fibrin attenuates contraction and reduces the spatial sorting of PS+
platelets during human WB clotting under flow.

6

2.2

Materials and Methods

Reagents and materials, blood collection, and preparation of collagen/TF on glass
slides
See Supplemental Methods for reagents and materials. Blood collection and
collagen/TF preparation has been previously described [13,14]. Blood collection protocol
and preparation of collagen/TF on glass slides are included in the Supplemental Methods.
8-channel microfluidic device experiments
After collagen/TF was patterned, an 8-channel device was placed over the
collagen strip and vacuum-sealed. Each channel in the device had a width of 250 µm and
a height of 120 µm. Then 35 µL of 0.5% bovine serum albumin (BSA) was added to each
of the 8 wells and perfused through each of the corresponding channels. After blood
collection, fluorophores were added: CD61 (platelets), fluorescent fibrinogen (fibrin), and
annexin V (PS). In control studies, we found that annexin V had a slightly inhibitory
effect on fibrin formation, but significant fibrin formation still occurred when annexin V
was present (Supp. Fig. S2-1). Then any agonists or controls were added (controls in each
experiment were 0.5% BSA of the same volume as the agonist); blood was then loaded to
each of the wells. A syringe with a fixed rate perfused the blood through the channels to
induce blood flow through the device. The syringes used were 1000 µL syringes
(Hamilton Co., Reno, Nevada), and the syringe pump (Harvard PHD 2000; Harvard
Apparatus, Holliston, MA) was set to 24 µL/min for experiments done at venous shear
rate (100 s-1). Blood was perfused through the device for 15 minutes. The epifluorescence
7

microscope (Olympus Ix81; Olympus America Inc, Central Valley, PA) captured
individual time frames at chosen locations with chosen wavelengths.
Contraction measurements
Contraction was measured as a percent based on clot length during the course of
an experiment (Supp. Fig. S2-2). The clot length was measured by drawing a line
(parallel to the direction of flow) down the center of the clot. Initial clot lengths were
measured at 9 minutes and final clot lengths were measured at 15 minutes. Percent
contraction was calculated as the difference between the initial and final clot lengths
divided by the initial clot length. Percent contraction measurements were made for
multiple clots for each condition, and the average was taken as the percent contraction.
Autocorrelation metric calculations for PS spatial sorting
To evaluate the differences in spatial distribution of PS at the end of experiments,
we developed an autocorrelation metric to quantify the extent of sorting of annexin V
fluorescence. Using the Matlab function “xcorr2,” we calculated the 2D autocorrelation
of an annexin V image of a clot. For an input matrix of size n x n, the “xcorr2” function
output an autocorrelation matrix of size (2n-1) x (2n-1). In order to calculate each of the
values in the autocorrelation matrix, the matrix was overlaid with itself in all possible
orientations. The elements of the overlaid matrices were then multiplied element by
element and the summation was input into the autocorrelation matrix in the
corresponding location to the matrix overlay. Thus, the center of the autocorrelation
matrix had the highest value because the center corresponds to a perfect overlay of the
8

matrix with itself. The autocorrelation matrix was then normalized to 1 by dividing every
matrix element by the maximum value in the matrix in order to eliminate any effects
from differences in fluorescence intensity (FI) between images. Next, since the
meaningful autocorrelation data was close to the center of the autocorrelation matrix, we
truncated the autocorrelation matrix to 20 pixels in each direction from the center pixel,
resulting in a 41 x 41 matrix. Truncating or cropping are commonly used in image
correlation spectroscopy when evaluating 2D autocorrelation matrices in order to better
fit the autocorrelation data to a Gaussian function [31–34]. Supplemental Figure S2-3
illustrates this matrix truncation. Lastly, the absolute value of the elements of this final
matrix were summed to give the autocorrelation metric. Example images (synthetic and
real) with corresponding autocorrelation metric values are illustrated in Supplemental
Figure S2-4.
Pearson correlation coefficient calculations for PS temporal sorting
To evaluate temporal changes in PS distribution, Pearson correlation coefficients
were calculated for annexin V images at 9 minutes and 15 minutes. The Pearson
correlation coefficient is commonly used to measure the degree of correlation between
two images by comparing them pixel by pixel [27,35,36]. We wanted to compare the
annexin V distribution between an early time point and the final time point of 15 minutes.
For the early time point, we chose 9 minutes as an intermediary time point that was not
too early for insufficient annexin V fluorescence, but not too late that the comparison to
the 15-minute image would be similar regardless of the condition. Supplemental Figure
S2-5 provides example images (synthetic and real) with corresponding Pearson
9

correlation coefficients. Images were first transferred into Matlab as pixel values in a
matrix. The Matlab function “corr2” was used to calculate the Pearson correlation
coefficient between the two matrices of pixel values, given by the following equation:

Where

and

are pixel values at location i for annexin V images at 9 minutes and 15

minutes, respectively, and

and

are the average FIs for images at 9 minutes and 15

minutes, respectively.
2.3

Results
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Figure 2-1. Inhibition of thrombin enhances PS sorting.
High CTI WB was perfused with and without PPACK over collagen/TF at an initial shear rate of 100s-1.
CD61, fluorescent fibrinogen, and annexin V were added to stain for platelets, fibrin, and PS, respectively.
Images of clots were taken in 90-second intervals for 15 minutes; example images are illustrated at 6
minutes (A) and 15 minutes (B) of CD61 (red), fluorescent fibrinogen (green), and annexin V (cyan).
Annexin V FI was measured during the course of the experiment as average FI ± standard deviation (C).
Contraction was measured as % contraction between 9 and 15 minutes in clots (D). An autocorrelation
metric was calculated for the final (15-minute) annexin V image for each clot as a measure of PS spatial
sorting (E). The Pearson correlation coefficient was calculated between 9- and 15-minute annexin V images
for each clot as a measure of PS temporal sorting (F). Data are from 4 different donors (N=4) and 28
individual clots (n=28). A.U. = arbitrary units

Inhibition of thrombin enhances PS sorting
We evaluated PS distribution in CTI-treated whole blood (WB) ± PPACK
perfused over collagen/TF. Phe-Pro-Arg-chloromethylketone (PPACK) is a potent
thrombin inhibitor [37]. As expected, no significant fibrin formation occurred in the
+PPACK channels, while fibrin formed in the control (no PPACK) channels (Fig. 2-1A
and B, upper panels; Supp. Fig. S2-6). Platelet images in both ±PPACK channels were
similar in morphology (Fig. 2-1A and B, upper panels) and FI (Supp. Fig. S2-6). Annexin
V distribution at early time points in both ±PPACK channels was similar (Fig. 2-1A
lower panel). However, at 15 minutes, the annexin V distribution changed
morphologically, with enhanced PS sorting in the +PPACK channels compared to the
control channels (Fig. 2-1B lower panel). Annexin V FI was similar between both
conditions throughout the experiment (Fig. 2-1C). Contraction was significantly more
pronounced (p <0.0001) in the +PPACK condition than in the control (Fig. 2-1D),
showing fibrin limits clot contraction.
We evaluated both the temporal changes of PS distribution within clots, as well as
differences in final PS spatial distribution between ±PPACK conditions. We used an
11

autocorrelation metric to evaluate the extent of PS spatial sorting at the final time point in
both conditions. Greater autocorrelation values correspond to greater PS spatial sorting,
while smaller values correspond to less PS spatial sorting (Supp. Fig. S2-4). We found
that +PPACK channels had a significantly greater autocorrelation metric than -PPACK
channels (p = 0.0008; Fig. 2-1E). We measured PS temporal sorting using the Pearson
correlation coefficient between annexin V images at 9 minutes and 15 minutes (Supp.
Fig. S2-5). Higher Pearson correlation coefficients indicate more similar images, which
correspond to less PS temporal sorting. Conversely, lower Pearson correlation
coefficients indicate less similar distributions, which correspond to more PS temporal
sorting. We found that +PPACK had a significantly lower Pearson correlation coefficient
than the control (0.31 and 0.79, respectively; Fig. 2-1F), indicating more PS temporal
sorting in the absence of fibrin.

12

Figure 2-2. Inhibition of fibrin polymerization enhances PS exposure and sorting.
High CTI WB was perfused with and without GPRP over collagen/TF at an initial shear rate of 100s-1.
CD61, fluorescent fibrinogen, and annexin V were added to stain for platelets, fibrin, and PS, respectively.
Images of clots were taken in 90-second intervals for 15 minutes; example images are illustrated at 6
minutes (A) and 15 minutes (B) of CD61 (red), fluorescent fibrinogen (green), and annexin V (cyan).
Annexin V FI was measured during the course of the experiment as average FI ± standard deviation (C).
Contraction was measured as % contraction between 9 and 15 minutes in clots (D). An autocorrelation
metric was calculated for the final (15-minute) annexin V image for each clot as a measure of PS spatial
sorting (E). The Pearson correlation coefficient was calculated between 9- and 15-minute annexin V images
for each clot as a measure of PS temporal sorting (F). Data are from 3 different donors (N=3) and 21
individual clots (n=21). A.U. = arbitrary units

Inhibition of fibrin polymerization enhances PS exposure and sorting
Since PPACK inhibits thrombin and subsequently prevents fibrin formation, we
next sought to determine how thrombin would affect PS sorting. We tested CTI-treated
WB ± GPRP perfused over collagen/TF. Gly-Pro-Arg-Pro (GPRP) inhibits fibrin
13

polymerization [38]. Unlike in the presence of PPACK, thrombin was not inhibited in the
presence of GPRP. As expected, no significant fibrin formation occurred in the +GPRP
channels, while fibrin formed in the control (no GPRP) channels (Fig. 2-2A and B, upper
panels; Supp. Fig. S2-7). Platelet FI was similar in both ±GPRP channels (Fig. 2-2A and
B, upper panels; Supp. Fig. S2-7). PS distribution in ±GPRP conditions at early time
points was similar (Fig. 2-2A lower panel), but enhanced PS sorting occurred in +GPRP
channels at later time points (Fig. 2-2B lower panel). Annexin V FI was initially similar
in both conditions until around 450s, when the +GPRP condition had a noticeable
increase in annexin V FI (Fig. 2-2C), with the final annexin V FI for +GPRP significantly
greater (p<0.0001) than -GPRP. This indicated that fibrin in the control condition may be
inhibiting thrombin (via antithrombin I activity) from contributing to PS exposure, while
thrombin in the +GPRP condition, where fibrin had not formed, was able to contribute to
increased PS exposure.
Similar to +PPACK results, contraction was significantly greater in the +GPRP
condition than in the control (Fig. 2-2D), further showing that fibrin limits contraction. In
terms of PS spatial sorting, +GPRP had a significantly (p<0.0001) greater autocorrelation
metric than the control, indicating much more PS spatial sorting in +GPRP (Fig. 2-2E).
Lastly, we found that the Pearson correlation coefficient for PS temporal sorting was
significantly lower in the +GPRP condition than in the control (0.30 and 0.83,
respectively; Fig. 2-2F), indicating greater PS temporal sorting for +GPRP channels.
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Figure 2-3. Fibrinolysis enhances PS sorting.
High CTI WB was perfused with and without tPA over collagen/TF at an initial shear rate of 100s-1. CD61,
fluorescent fibrinogen, and annexin V were added to stain for platelets, fibrin, and PS, respectively. Images
of clots were taken in 90-second intervals for 15 minutes; example images are illustrated at 6 minutes (A)
and 15 minutes (B) of CD61 (red), fluorescent fibrinogen (green), and annexin V (cyan). Annexin V FI was
measured during the course of the experiment as average FI ± standard deviation (C). Contraction was
measured as % contraction between 9 and 15 minutes in clots (D). An autocorrelation metric was calculated
for the final (15-minute) annexin V image for each clot as a measure of PS spatial sorting (E). The Pearson
correlation coefficient was calculated between 9- and 15-minute annexin V images for each clot as a
measure of PS temporal sorting (F). Data are from 3 different donors (N=3) and 22 individual clots (n=22).
A.U. = arbitrary units

Fibrinolysis enhances PS sorting
We then evaluated the effect of fibrinolysis on PS distribution by testing CTItreated WB ± tissue plasminogen activator (tPA) perfused over collagen/TF. Plasminogen
can localize on the ballooned “cap” of PS-exposing platelets [39]. The role of fibrinolysis
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in PS sorting at the whole thrombus level is more complex since fibrin is present, then
subsequently dissolves. At early time points, fibrin formed in both the presence and
absence of tPA (Fig. 2-3A upper panel). However, as fibrin continued to form, tPAgenerated plasmin dissolved the fibrin until most of the fibrin had been solubilized (Fig.
2-3B upper panel). Fibrin FI for both conditions was similar until around 300s, where the
fibrin FI for the +tPA condition soon plateaued and then decreased, while the control (no
tPA) fibrin FI continued to increase throughout the experiment (Supp. Fig. S2-8). Platelet
FI for ±tPA conditions was nearly the same throughout the course of the experiment
(Supp. Fig. S2-8). Annexin V distribution for both conditions was fairly similar at early
time points (Fig. 2-3A lower panel), but annexin V in +tPA condition began to sort more
than in control at later time points (Fig. 3B lower panel), similar to annexin V distribution
in +PPACK and +GPRP conditions. Annexin V FI was similar for both conditions
throughout the experiment (Fig. 2-3C) with no significant difference in final annexin V
FI.
Contraction was significantly greater (p = 0.0028) in +tPA channels than in
control (Fig. 2-3D). The autocorrelation metric suggested greater PS spatial sorting in
+tPA than in -tPA, as +tPA had a statistically greater autocorrelation metric than -tPA
condition (p=0.018; Fig. 2-3E). The Pearson correlation coefficient was significantly
lower in the +tPA condition than in control (Fig. 2-3F), indicating greater PS temporal
sorting in +tPA, similar to +PPACK and +GPRP conditions.
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Figure 2-4. PS sorting is enhanced in the absence of procoagulant conditions (no TF).
High CTI WB was perfused with and without PPACK over collagen (no TF) at an initial shear rate of
100s-1. CD61, fluorescent fibrinogen, and annexin V were added to stain for platelets, fibrin, and PS,
respectively. Images of clots were taken in 90-second intervals for 15 minutes; example images are
illustrated at 6 minutes (A) and 15 minutes (B) of CD61 (red), fluorescent fibrinogen (green), and annexin
V (cyan). Annexin V FI was measured during the course of the experiment as average FI ± standard
deviation (C). Contraction was measured as % contraction between 9 and 15 minutes in clots (D). An
autocorrelation metric was calculated for the final (15-minute) annexin V image for each clot as a measure
of PS spatial sorting (E). The Pearson correlation coefficient was calculated between 9- and 15-minute
annexin V images for each clot as a measure of PS temporal sorting (F). Data are from 3 different donors
(N=3) and 20 individual clots (n=20). A.U. = arbitrary units

PS sorting is enhanced in the absence of procoagulant conditions (no TF)
We tested CTI-treated WB ± PPACK perfused over collagen (no TF). With no
extrinsic pathway available to trigger fibrin formation, we expected both conditions
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(±PPACK) to have little to no fibrin formation, and therefore significant PS sorting.
Platelet deposition and FI were nearly identical between both conditions and as expected,
little to no fibrin formed in either condition (Figure 2-4A and B, upper panels; Supp. Fig.
S2-9). Annexin V distribution was more evenly distributed at early time points for both
±PPACK (Fig. 2-4A lower panel), but by 15 minutes, PS had sorted in both conditions
(Fig. 2-4B lower panel). Annexin V FI was similar in both ±PPACK conditions
throughout the experiment (Fig. 2-4C), with no statistical difference between final
annexin V FIs.
There was no significant difference in contraction between ±PPACK, as expected
because neither condition had fibrin formation (Fig. 2-4D). Contraction was pronounced
in both conditions, similar to the magnitude of contraction in +PPACK in Figure 2-1 and
+GPRP in Figure 2-2. There was no statistical difference in the autocorrelation metric
between ±PPACK conditions, suggesting the same degree of PS spatial sorting occured
in both conditions (Fig. 2-4E). PS temporal sorting was prevalent in both conditions,
indicated by the relatively low Pearson correlation coefficients, with no significant
difference between ±PPACK (Fig. 2-4F).
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Figure 2-5. PS sorting correlates with contraction, and correlates inversely with fibrin FI.
The Pearson correlation coefficient between 9- and 15-minute images of annexin V fluorescence was
calculated as a measure of PS temporal sorting for each clot. The final fibrin FI (at 15 minutes) was
measured for each clot. The % contraction between 9- and 15-minute annexin V images was also measured
for each clot. (A) The graph compares the final fibrin FI to the Pearson correlation coefficient for PS
temporal sorting for each clot tested. (B) The graph compares the % contraction to the Pearson correlation
coefficient for PS temporal sorting for each clot tested. All conditions tested are included (TF controls refer
to -PPACK, -GPRP, and -tPA controls). Data points include all data from Figures 2-1 through 2-4.

Contraction correlates with PS sorting, but fibrin attenuates contraction and PS
sorting
During experiments, we observed differences in thrombus contraction between
clots that did and did not have fibrin. This was in agreement with recent research that
fibrin limits clot contraction in vivo [30]. We investigated if PS sorting correlated with
fibrin. Our results for fibrin FI and PS temporal sorting showed a strong correlation (R2 =
0.863; Fig. 2-5A). Clots with greater fibrin FI had greater Pearson correlation coefficients
and thus less PS temporal sorting. We also investigated the relation between PS sorting
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and contraction. The results showed that the Pearson correlation coefficient correlated
inversely with % contraction (R2 = 0.721; Fig. 2-5B). Clots with greater % contraction
had smaller Pearson correlation coefficients, and thus greater PS temporal sorting.

Figure 2-6. Extent of PS sorting and % contraction is consistent across similar fibrin conditions.
We compared the % contraction in clots where fibrin was inhibited or dissolved (+PPACK, +GPRP, +tPA,
±PPACK no TF) and clots where fibrin formed (-PPACK, -GPRP, -tPA) (A). The Pearson correlation
coefficients for PS temporal sorting for all conditions tested were compared to each other (B). The %
contraction for all conditions tested were compared to each other (C). Schematic of PS exposure and PS+
platelet sorting (D). Green lines with circles indicate contributing driving factors for an action (e.g.
contraction contributes to PS+ platelet sorting). Red lines with bars indicate inhibiting or limiting factors for
an action (e.g. fibrin limits contraction).

We noted that the 3 control conditions that had normal fibrin formation (-PPACK,
-GPRP, and -tPA) all had similarly high Pearson correlation coefficients (0.79, 0.83, and
0.76, respectively), indicating much less PS temporal sorting (Fig. 2-6A). All other
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conditions (+PPACK, +GPRP, +tPA, ±PPACK no TF) that resulted in little to no final
fibrin FI had similarly low Pearson correlation coefficients (0.31, 0.30, 0.43, 0.32, and
0.31, respectively), indicating much greater PS temporal sorting. The Pearson correlation
coefficient for +tPA was slightly greater (0.43) than the other conditions without fibrin,
likely because initial fibrin formation in +tPA resulted in a small, residual amount of
fibrin present by 15 minutes.
We also wanted to compare the % contraction across all conditions (Fig. 2-6B).
The conditions with normal fibrin formation had similar magnitudes of contraction, at
around 2-4% on average. Conditions where fibrin formation was inhibited (+PPACK,
+GPRP, ±PPACK no TF) all had similarly high % contraction, at around 10-12% on
average. Although +tPA had significantly greater contraction than conditions with fibrin,
contraction was slightly less (average = 7.6%) than conditions where fibrin formation
was inhibited. This may be due from some residual or transient low levels of fibrin that
were not fully lysed by 15 minutes. This slightly decreased contraction in +tPA is in
agreement with the Pearson correlation for +tPA being slightly higher (0.43) than in
conditions where fibrin is inhibited (0.31, 0.30, 0.32, and 0.31), further supporting the
inverse relationship between Pearson correlation coefficient and % contraction. To
evaluate the relation between fibrin and contraction, we compared the final fibrin FI to %
contraction for each clot. Clots with no fibrin formation (+PPACK, +GPRP, ±PPACK no
TF) or significant fibrinolysis (+tPA) had a 3.6X greater clot contraction than clots where
fibrin formed normally (-PPACK, -GPRP, and -tPA), which was significantly greater
(Fig. 2-6C). Lastly, we illustrated how PS exposure and PS sorting relate to the
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coagulation cascade (Fig. 2-6D), noting that fibrin attenuates contraction and subsequent
PS sorting.

Figure 2-7. Pearson correlation coefficient measures PS temporal sorting and autocorrelation metric
measures PS spatial sorting.
Example images of PS distribution of clots from GPRP, PPACK, tPA, and control experiments at 15
minutes. Higher Pearson correlation coefficients indicate more similar distributions between 9 minute and
15 minute images; lower Pearson correlation coefficients indicate different distributions between 9 and 15
minutes images. Higher autocorrelation metric values indicate a more sorted distribution of PS at 15
minutes; lower autocorrelation metric values indicate a more mixed distribution of PS at 15 minutes.

The consistency in Pearson correlation coefficient values for conditions where
fibrin was inhibited (Fig. 2-6A) demonstrates the robustness of using a Pearson
correlation coefficient to measure PS temporal sorting. Similarly, the autocorrelation
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metric used to evaluate the extent of PS spatial sorting consistently showed significant
differences between ±fibrin conditions. The autocorrelation metric values for GPRP were
notably higher than for PPACK and tPA, suggesting free thrombin availability may have
contributed to PS sorting. Figure 2-7 illustrates how Pearson correlation coefficients
decreased from similar to different distributions (between 9 and 15 minutes), and how the
autocorrelation metric decreased from sorted to mixed distributions (at 15 minutes).
PS sorting occurs in the presence of fibrin, but PS sorting is greater when fibrin is
inhibited or lysed
We also evaluated the differences in autocorrelation metric values between
images at 6 minutes and 15 minutes in clots (Supp. Fig. S2-10). We found that for all
conditions, the average autocorrelation metric increased significantly from 6 to 15
minutes, supporting the previous finding by Nechipurenko, et al. that some degree of PS
sorting occurs in the presence of fibrin [28]. We note here that at 6 minutes, there were
no statistical differences in autocorrelation metric values between +PPACK, +GPRP, and
+tPA and their respective controls (Supp. Fig. S2-10), but there were statistical
differences at 15 minutes, with +PPACK, +GPRP, and +tPA all statistically greater (more
sorted) than their controls (Fig. 2-1E, Fig. 2-2E, Fig. 2-3E). While our results support the
finding that PS sorting can occur to some extent with fibrin present, fibrin plays an
attenuating role limiting the extent of PS sorting.
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2.4

Discussion
We performed an in vitro study with physiological human blood flow conditions

using microfluidics to evaluate the spatial distribution of PS and the role of fibrin and
fibrinolysis. In new results, we demonstrate that clots without fibrin exhibit enhanced PS
sorting and clot contraction compared to clots with fibrin. We first showed that in
PPACK-treated WB, annexin V spatially and temporally sorted into areas of locally high
and low FI, confirming a heterogeneous localization around the periphery of the platelet
mass previously reported by others [27,28]. By comparison, non-PPACK-treated WB had
a more homogeneous annexin V distribution throughout the platelet masses. We showed
that with thrombin present, PS still sorted in the absence of fibrin polymerization. In the
case of fibrinolysis, our results showed that as fibrin breaks down, PS spatial and
temporal sorting subsequently occurred. In preventing extrinsic pathway coagulation by
removing TF, PS sorting occurred regardless of whether PPACK is present. As fibrin
limits contraction, PS sorting correlated with clot contraction and correlated inversely
with fibrin FI. Using both spatial and temporal image correlation metrics for PS sorting
under diverse pharmacological conditions, we quantitatively demonstrated that fibrin
limited the extent of contraction and subsequent PS sorting.
Recent studies have explored the spatial distribution of annexin V on platelets and
the role of clot contraction in driving PS+ platelets to the clot periphery [27,28].
Additionally, fibrin stiffens clots and limits contraction [29,30,40,41]. While
Nechipurenko, et al. [28] observed ~6 PS+ platelets at the periphery of a platelet mass
when fibrin was present (Ref. [28] Supp. Fig. 9), there was no quantification of PS+
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platelet sorting as a function of fibrin level. Munnix, et al. [27] noted that PS at the
periphery seemed to appear from initial stages of clot growth, while Nechipurenko, et al.
[28] observed that PS+ platelets translocate to the periphery via contraction. We sought to
determine if blocking fibrin enhances clot contraction and PS+ platelet sorting. We show
fibrin limited contraction (Fig. 2-6C) and PS+ platelet sorting was attenuated as fibrin
levels increased (Fig. 2-5A). It is worth noting a limitation in this study is the use of
microfluidics. While in vitro studies can help elucidate important phenomena, future in
vivo studies should be considered to further validate findings in this study.
Nechipurenko, et al. [28] observed no noticeable difference in PS sorting between
clots with and without fibrin. However, this conclusion was drawn from a single
observation of ~6 individual PS+ platelets at the periphery of a platelet mass with fibrin
present. While our results are in agreement that there is a detectable degree of PS sorting
in the presence of fibrin (Supp. Fig. S2-10), we clearly observed much greater PS sorting
when fibrin is inhibited. In our assay, at lower shear rates, thousands of platelets for
analysis cover the full 250 µm x 250 µm collagen patch. At higher shear rates, platelet
deposition and embolism is much more variable and heterogeneous. Thus, we explored a
lower shear rate to allow highly consistent platelet deposition across different donors and
different experiments.
We developed two independent imaging algorithms to quantify localization
processes: cross correlation and autocorrelation. Cross correlation analysis compared 2
images at different time points (9 minutes and 15 minutes) to give a Pearson correlation
coefficient as an indication of PS temporal sorting. Autocorrelation analysis compared an
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image with itself (image at 15 minutes) to give an autocorrelation metric as an indication
of PS spatial sorting. There was a difference in sensitivity to detect PS changes between
the Pearson correlation (measuring temporal changes) and the autocorrelation metric
(measuring spatial heterogeneity). When fibrin is inhibited or lysed, the temporal changes
in PS distributions were more pronounced than the spatial differences in PS distributions.
Pearson correlation addressed the question “does the PS distribution change?” while the
autocorrelation metric then goes further, addressing “how does the distribution change
(i.e. more of less spatially sorted)?”
Our observation that fibrin limits contraction, confirming what previous studies
have found, was the primary reason for the difference in PS sorting between clots with
and without fibrin. Samson, et al. [30] observed reduced clot contraction when
endogenous fibrinolysis was blocked, suggesting fibrin contributes to clot rigidity. Red
blood cells (RBCs) may also play a role in clot contraction. Fibrin cross-linking due from
FXIIIa has been shown to be important for RBC retention in clots [42,43]. Tutwiler, et al.
[40,41] showed that the presence of RBCs in clots decreases the extent of clot
contraction. Thus, these studies suggest clots with cross-linked fibrin may be more rigid
and contain RBCs, which would limit clot contraction compared with clots without fibrin,
as we have seen in our results.
In the case of tPA experiments, +tPA showed statistically greater contraction,
greater autocorrelation metric values, and greater PS temporal sorting than -tPA (Fig. 23); however, these differences were not as pronounced as they were with +PPACK or
+GPRP and their respective controls. This was likely because of two processes. First, the
26

initial fibrin formation and some residual fibrin present by the end of experiments may
have caused +tPA contraction to be slightly less and the Pearson correlation coefficient to
be slightly more than in +PPACK or +GPRP. Second, the transience of fibrinolysis tends
to result in greater variability in when and to what extent fibrin is lysed compared to
GPRP or PPACK, which may have caused statistical differences to be less pronounced in
+tPA than in +PPACK or +GPRP.
Interestingly, GPRP significantly increased PS exposure compared to control
conditions, while PPACK and tPA showed no significant differences in annexin V FI
compared to control. PS exposure occurs as a result of increased Ca2+ flux, which can be
achieved by stimulating GPVI (in this case, via collagen) or PAR1 or PAR4 (via
thrombin) [15,44]. We have previously shown that fibrin captures >85% of locally
generated thrombin [45]. In the presence of GPRP, thrombin flux increased steadily until
~500s, and then saw an accelerated increase most likely due from FXIa-dependent
thrombin amplification [45]. Interestingly, this correlates with our finding here that the
annexin V FI increased steadily for both ±GPRP conditions until ~450s, where annexin V
FI in the +GPRP condition then increased much more quickly than in the control (Fig. 22C). This suggests that increased thrombin available in the +GPRP condition contributed
significantly to increased PS exposure.
In the +GPRP condition, the PS+ platelet masses were notably larger than other
conditions, which ultimately caused the PS distribution at 15 minutes to be more
heterogeneous (or sorted) and thus, the autocorrelation values for this condition were
greater. With GPRP present, the lack of fibrin may be related to (1) increased local
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thrombin (loss of antithrombin I activity) and (2) more locations available to fill with
platelets that would have contained fibrin.
These microfluidic results with human blood support a role of fibrin in
consolidating the clot, both mechanically and biologically. Restriction by fibrin of PS
distribution may limit continued thrombin generation, an outcome that is also fortified by
the antithrombin I activity of fibrin. The mitigating role of fibrin on contraction may set
the later stage for fibrinolytic resolution of a clot. This consolidating role of fibrin is also
consistent with our previous observation that fibrin also limits NETosis in sterile
occlusive human thrombi [46]. Intrathrombus fibrin limits a number of processes during
thrombosis under flow. For example, fibrin binds thrombin [45,47], reduces the
formation of shear-induced NETosis [46], and, as seen in this study, attenuates clot
contraction and the degree of PS+ platelet sorting.
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CHAPTER 3: THE ROLE OF ADP AND TXA2 IN LIMITING CONTRACTION

3.1

Introduction
Clot contraction is an important process that occurs in hemostasis to ensure clot

resolution and return of unobstructed blood flow. Contraction involves a number of
elements, including fibrin, fibrinogen, platelets, RBCs, von Willebrand factor (VWF),
and collagen, among others. The process of clot contraction actually consists of a number
of distinct processes that occur, including, but not limited to, reduction of clot size
[2,3,40,48], stiffening of the clot matrix [3,4,49], deformation of RBCs [50,51], extrusion
of procoagulant platelets [28,52], and redistribution of fibrin [3,48]. The significance of
contraction as a process can be seen in diseases where there are defects in non-muscle
myosin, resulting in increased bleeding [6]. Additionally, reduced contraction can lead to
increased risk of venous thromboembolism [53,54], which could ultimately lead to acute
ischemic stroke [55].
Platelet contraction via cytoskeletal actin and myosin plays a key role in
strengthening and stabilizing clots [6,56,57]. Non-muscle myosin is a driving force of
platelets’ contractile ability; when blebbistatin is present to inhibit non-muscle myosin,
clot contraction is significantly reduced [6,30,57]. Although platelets contribute
significantly to clot contraction, many viscoelastic measurement techniques to evaluate
contraction require the presence of thrombin and/or fibrin, which does not allow for the
independent evaluation of the contractile ability of platelets [3,58–60]. Additionally,
many of these contraction measurement techniques are not performed under physiologic,
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or near-physiologic, conditions. Our in vitro microfluidic system allows us the ability to
observe clot development, including contraction, on a macro scale, evaluating multiple
platelet aggregates in a fully formed clot, in a physiologically relevant environment.
Upon binding of collagen and VWF, platelets release ADP and thromboxane A2
(TXA2), which propagate further activation of nearby platelets to contribute to the
stability of a growing platelet mass [49,61,62]. As shown in the core/shell model, Stalker,
et al. suggest that ADP and TXA2 moderate the growth of the P-selectin(-) shell region of
the clot, while ADP and TXA2 inhibitors have a limited effect on the stable core region,
making these inhibitors ideal for limiting platelet accumulation while also preventing
bleeding [16]. As such, TXA2 inhibitors like aspirin and ADP inhibitors like clopidogrel
are commonly used in a number of patient conditions, but the effects of these types of
drugs on clot contraction is not fully elucidated. Ting, et al. [49] evaluated ADP and
TXA2 inhibitors on platelet contractile forces using a microfluidic device with a block
and post. They observed that acetylsalicylic acid (ASA, aspirin), a COX-1 inhibitor that
prevents TXA2 production, and 2-MeSAMP, a P2Y12 inhibitor that prevents ADP
signaling, significantly reduce platelet forces and aggregate size. However, these
experiments were performed at 8000 s-1, which is at the very high end of arterial flow
shear rates [63]. Additionally, the block and post device to measure platelet contractile
force has limited physiological relevance.
Here, we wanted to evaluate contraction in our microfluidic assay that closely
mimics in vivo dynamics of a growing clot. We also evaluated three platelet antagonists:
ASA, 2-MeSAMP, and MRS-2179, which is a P2Y1 inhibitor that prevents ADP
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signaling. We added these platelet antagonists to PPACK-treated whole blood (WB), to
ensure thrombin and fibrin inhibition. This allowed us to focus primarily on plateletplatelet interactions and not platelet-fibrin interactions. We wanted to differentiate
contraction of platelet aggregates in both the core and shell regions, utilizing CD61 and
P-selectin antibodies to measure aggregate contraction in different regions of the clot.
Additionally, we measured contraction using two different algorithms that we developed,
one for global contraction, measuring clot contraction on a macro scale, looking at fully
formed clots with multiple platelet aggregates; and one for local contraction, measuring
clot contraction on a micro scale, looking at how individual platelet aggregates contract
within a larger clot. We found that both ADP and TXA2 inhibitors limited global
aggregate contraction, and had an additive effect when used in combination. However,
TXA2 inhibition had a significant effect on reducing local aggregate contraction, while
ADP inhibition did not. Lastly, P-selectin+ platelets demonstrated limited global and
local aggregate contraction, both in the presence and absence of any ADP or TXA2
inhibition. Taken together, the results of this study suggest ADP and TXA2 inhibition
may limit aggregate contraction on a macro scale, and TXA2 inhibition in particular may
limit aggregate contraction on a micro scale, which have fundamental repercussions in
terms of clot development and clot resolution.
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3.2

Materials and Methods

Reagents and Materials
Reagents were prepared and kept at appropriate conditions prior to use in
experiments: Phe-Pro-Arg-chloromethylketone (PPACK; EMD Millipore, Burlington,
MA), acetylsalicylic acid (ASA; Sigma-Aldrich, St. Louis, MO), 2-methylthioadenosine
5’-monophosphate (2-MeSAMP; Sigma-Aldrich, St. Louis, MO), MRS-2179 (Tocris,
Minneapolis, MN), AF647 anti-human CD62P (P-Selectin) antibody (BioLegend, San
Diego, CA), AF488 mouse anti-human CD61 (Bio-Rad Laboratories, Hercules, CA),
Sigmacote (Sigma-Aldrich, St. Louis, MO), type I fibrillar collagen (Chrono-log,
Havertown, PA).
Preparation of microfluidic device with collagen surface
Glass slides were rinsed with ethanol and dried with filtered air. Slides were then
rinsed with Sigmacote and then DI water to create a hydrophobic surface. A patterning
device was vacuum-sealed to the glass slide. Fibrillar collagen (5 µL) was perfused
through the patterning channel (250 µm wide × 60 µm high) of the patterning device to
create a 250 µm-wide strip of collagen for all experiments, as previously described
[13,14,47,64]. Finally, collagen was rinsed with 20 µL 0.5% bovine serum albumin
(BSA) buffer, and the patterning device was then removed from the glass slide, leaving a
strip of collagen.
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Blood collection and preparation
Blood donors were self-reported as medication-free for at least 7 days prior to
blood collection. All donors provided informed consent under approval of the University
of Pennsylvania Institutional Review Board. Blood was obtained via venipuncture into a
syringe containing PPACK (1:100 v/v; final concentration of 100 µmol/L). P-selectin and
anti-CD61 fluorophores were then added to whole blood (WB), both in a 1:50 v/v
dilution. ADP and TXA2 inhibitors were added where needed, resulting in the following
final concentrations: ASA (100 µM), 2-MeSAMP (100 µM), MRS-2179 (10 µM).
8-channel microfluidic device contraction assay
After collagen was patterned, an 8-channel microfluidic device was placed over
the collagen strip and vacuum-sealed, with channels perpendicular to the collagen strip.
Thus, each channel contained a 250 µm x 250 µm collagen patch. Each channel had a
height of 120 µm. Then 35 µL of 0.5% bovine serum albumin (BSA) was added to each
of the 8 wells and perfused through each channel. After blood was drawn, fluorophores
were added, followed by ADP or TXA2 inhibitors (ASA, 2-MeSAMP, and/or MRS2179) or their corresponding controls. ASA stock was dissolved in 10% DMSO, with a
final concentration of 0.1% DMSO in blood (1:100 ASA dilution). The control for ASA
was a 10% DMSO solution (1:100 dilution; 0.1% DMSO final concentration in blood). 2MeSAMP and MRS-2179 were both dissolved in water; the control for 2-MeSAMP and
MRS-2179 was HBS. Once agonists or controls were added to blood, blood of varying
conditions was loaded into the corresponding wells. Blood was perfused through
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channels by a 1000 µL syringe (Hamilton Co., Reno, Nevada) with a fixed rate to induce
blood flow. The syringe pump (Harvard PHD 2000; Harvard Apparatus, Holliston, MA)
was set to 24 µl/min, resulting in an initial venous shear rate of 100s-1 for all experiments.
Blood was perfused for 7.5 min, and then flow was paused (0 s-1) at 7.5 min, for the
remaining 7.5 min of the experiment, for a total experiment time of 15 minutes. The
epifluorescence microscope (Olympus Ix81; Olympus America Inc, Central Valley, PA)
captured individual time frames at chosen locations with chosen wavelengths.
Image analysis
Fluorescence measurements
Fluorescence intensity (FI) of fluorophores (CD61 and P-selectin) was
measured over time, with images of each clot uploaded and compiled into a time
sequence in ImageJ. The initial image (t = 0s) was subtracted from subsequent
images to subtract for any background fluorescence. Fluorescence was measured
using a rectangular subsection of the central 2/3 of the clot area, to avoid any edge
effects. FI values were exported to Matlab, where plots were made of the FI
values and experiment time. Values in plots are average ± standard deviation of FI
values over time.
Global contraction measurements
Images of CD61 and P-selectin fluorescence were uploaded to ImageJ. We
wanted to observe the extent of contraction in clots on the collagen surface, which
was 250 µm x 250 µm. However, in many instances, platelets aggregated above
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and below the collagen surface in the direction of flow. To include this in our
contraction measurements, images of individual clots were made to be 250 µm x
300 µm, with the 300 µm dimension in the direction of flow incorporating all
platelets in the clot above and below the collagen strip. Images were then
uploaded to Matlab and binarized to allow for automated contraction
measurements. The threshold for binarizing images was chosen to be half of the
average fluorescence of the image (Supp. Fig. 3-1). Binary images had platelets
represented in white, and empty space in black.
Once images were binary in Matlab, we measured global contraction by
building a Matlab algorithm that automatically drew 5 lines through the central
portion of the clot in the same direction as flow. One line was drawn at the middle
(of the x direction) pixel of the clot. Four additional lines were drawn at the
following locations, relative to the middle line: -50 pixels, -25 pixels, + 25 pixels,
and +50 pixels (each in the x direction). Each line was drawn from the top most
platelet (white) pixel to the bottom most platelet (white) pixel (in the y direction).
This was done for images at 7.5 and 15 min of the same clot. The lengths of the
five lines at 7.5 min were averaged, as were the lengths of the five lines at 15 min.
The average lengths at 7.5 min and 15 min were then used to calculate the percent
global contraction (Supp. Fig. 3-2). This was done for both CD61 and P-selectin
images.

35

Local contraction measurements
In addition to global contraction, we used binary images in Matlab to
calculate local contraction for CD61 and P-selectin images. Binary images at 7.5
min and 15 min for a particular clot were measured in Matlab for their percent
platelet coverage, or percent of the image containing white space (representing
platelets). The percent coverage between 7.5 min and 15 min images were each
used to calculate local contraction (Supp. Fig. 3-3). This was done for both CD61
and P-selectin images.
Statistical Analyses
Statistical differences between conditions were calculated using unpaired Welch’s
t-tests in GraphPad (ns signifies p > 0.05).
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3.3

Results

Figure 3-1. ASA, 2-MeSAMP, and MRS-2179 have an additive effect on limiting platelet deposition,
but do not have an additive effect on limiting P-selectin display.
PPACK WB with and without ASA, 2-MeSAMP, and MRS-21279 was perfused over collagen at 100 s-1
for 7.5 min, then flow was stopped for 7.5 min. CD61 fluorophore was added to label platelets, with images
taken at 7.5 min (A) and 15 min (B). P-selectin fluorophore was added to label platelet activation via alphagranule release, with images taken at 7.5 min (C) and 15 min (D).
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Figure 3-2. Quantitative fluorescence data from Figure 3-1.
PPACK WB with and without ASA, 2-MeSAMP, and MRS-21279 was perfused over collagen at 100 s-1
for 7.5 min, then flow was stopped for 7.5 min. Platelet (A) and P-selectin (B) fluorescence intensities were
measured throughout the course of the experiment amongst the different conditions. Delta signifies change
from 100s-1 to 0s-1 flow rate at 7.5 min. (N = 3 donors, n = 6 clots for each panel; A.U. = arbitrary units)

ASA, 2-MeSAMP, and MRS-2179 have an additive effect on limiting platelet
deposition.
To measure how ADP and TXA2 inhibition affect clot contraction, we perfused
PPACK whole blood (WB) with and without ASA, 2-MeSAMP, and MRS-2179 over
collagen at 100s-1 for 7.5 min, followed by stopping flow for 7.5 min. ASA, 2-MeSAMP,
and MRS-2179 were each added individually, and in combination with each other. We
added CD61 fluorophore to WB to label for platelets. By 7.5 min, platelets had deposited
normally in control conditions, while there appeared to be slightly reduced platelet
deposition in +ASA conditions, and considerably reduced platelet deposition in +238

MeSAMP, +MRS-2179, and all combinatorial conditions (Fig. 3-1A, 3-2A). From 7.5
min to 15 min, with flow stopped, platelet fluorescence intensity (FI) in control continued
to increase slightly, but at a slower rate than from 0 min to 7.5 min. This increase in
platelet FI while flow had stopped was likely due from contraction. All other conditions
remained nearly constant from 7.5 min to 15 min (Fig. 3-1B, 3-2A). Notably, the
combinatorial conditions (with 2 or 3 ADP and/or TXA2 inhibitors present) had lower
final FI than either of the conditions with only one inhibitor present, suggesting an
additive effect of ASA, 2-MeSAMP, and MRS-2179 on reducing platelet deposition.
ASA, 2-MeSAMP, and MRS-2179 did not have an additive effect on limiting Pselectin display.
In addition to CD61, we also added P-selectin fluorophore to WB to label for
alpha-granule release. By 7.5 min, P-selectin display was prominent in each condition,
with the control showing slightly greater fluorescence than the conditions with
ADP/TXA2 inhibitors present (Fig. 3-1C and 3-2B). From 7.5 min to 15 min, with flow
stopped, P-selectin fluorescence continued to increase steadily in the control condition
(Fig. 3-1D and 3-2B). This continued increase was greater than the increase in platelet
deposition from 7.5 min to 15 min, indicating that the increase in P-selectin from 7.5 min
to 15 min was likely not solely due from contraction. Additionally, P-selectin display in
conditions with ADP and/or TXA2 inhibitors continued to slightly increase from 7.5 min
to 15 min, which was not the case for platelet deposition. Like platelet deposition, Pselectin display appeared to be markedly reduced by the presence of any ADP or TXA2
inhibitors. However, unlike with platelet deposition, ADP and/or TXA2 inhibition did not
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appear to have a strong additive effect on reducing P-selectin fluorescence, as differences
in final fluorescence among different conditions with ADP and/or TXA2 inhibitors
showed fairly similar FI values, with a few, minimal statistical differences between
different conditions (Fig. 3-2B).

Figure 3-3. P-selectin+ platelets have limited global and local contraction; ASA, 2-MeSAMP, and
MRS-2179 have a limiting effect on global platelet contraction, while only ASA limits local platelet
contraction.
Images from Figure 3-1 were measured for global and local contraction. Global contraction measured the
change in distance in clot length between 7.5 min and 15 min images of a clot. Local contraction measured
the change in percent area coverage of a clot between 7.5 min and 15 min. Global contraction for platelets
(A), local contraction for platelets (B), global contraction for P-selectin (C), and local contraction for Pselectin (D) were compared among the various conditions. (N = 3 donors, n = 6 clots for each panel;
*p<0.05, **p<0.01, ***p<0.001)
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ASA, 2-MeSAMP, and MRS-2179 have a limiting effect on global aggregate
contraction
Global and local contraction measurements were made based on images taken from
experiments in Figure 3-1. Global contraction for platelet aggregates was measured as the
% change in distance from the top edge of the clot to the bottom edge, between 7.5 min
and 15 min images (Fig. 3-3A). Measurements for the control condition showed
pronounced contraction. With individual ADP or TXA2 inhibitors added (ASA alone, 2MeSAMP alone, or MRS-2179 alone), contraction was significantly reduced. Contraction
was reduced even further when inhibitors were added in combination (ASA + 2MeSAMP, ASA + MRS-2179, and 2-MeSAMP + MRS-2179), and decreased the most
when all three inhibitors were present. This demonstrated an additive effect of ADP
and/or TXA2 inhibitors on reducing global aggregate contraction.
Like global contraction, local contraction for platelet aggregates was pronounced under
control conditions (Fig. 3-3B). However, unlike global contraction, local contraction for
platelet aggregates was affected differently by ADP and/or TXA2 inhibition. Conditions
with 2-MeSAMP and MRS-2179 showed no consistent pattern in altering local aggregate
contraction relative to control, suggesting ADP inhibition did not have much of an effect
on local aggregate contraction. However, conditions with ASA consistently showed
reduced local contraction, with significant differences. This suggested that TXA2
inhibition may play a role in limiting local platelet aggregate contraction.
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P-selectin+ platelets have limited global and local contraction
In addition to CD61+ platelets, we also measured global (Fig. 3C) and local (Fig.
3D) contraction in P-selectin images. Global and local contraction for P-selectin in
control was minimal relative to global and local aggregate (CD61+) contraction. This
suggests that the P-selectin+ core of the clot was less contractile relative to the Pselectin(-) shell region of the clot under control conditions. Additionally, ADP or TXA2
inhibition alone, or in combination, showed limited global and local contraction. Some
ADP and/or TXA2 conditions showed marginally higher % contraction than control, but
there did not appear to be a noticeably significant trend. Thus, the P-selectin+ core of the
clot was generally less contractile, and was not significantly affected by ADP or TXA2
inhibition.

42

Figure 3-4. Platelet fluorescence correlates with global contraction.
Final platelet fluorescence and % global contraction were graphed for individual clots (A). Average
fluorescence and contraction values for each condition were also graphed (B). (N = 3 donors, n = 6 clots for
B; A.U. = arbitrary units)

Platelet fluorescence correlates with global contraction
As observed in Figure 3-2A, platelet FI was greatest for control, while TXA2
inhibition with ASA noticeably reduced platelet FI. ADP inhibition (via either 243

MeSAMP or MRS-2179) significantly reduced platelet FI relative to control, and
combinations of ADP and TXA2 inhibitors reduced platelet FI even further, suggesting
ADP and TXA2 inhibition had an additive effect on reducing platelet deposition. In
Figure 3-3A, we saw contraction was greatest in control, and then significantly reduced
when ADP and TXA2 inhibitors were present. ADP and TXA2 inhibition together
showed the greatest reduction in global aggregate contraction, again suggesting ADP and
TXA2 may have had an additive effect on reducing global aggregate contraction.
Because of the potential additive effects of ADP and TXA2 inhibition on platelet
deposition and global aggregate contraction, we wanted to see how platelet deposition
and aggregate contraction correlated for each clot and for each condition. To do this, we
compared the % global aggregate (CD61+) contraction and platelet FI for each clot (Fig.
3-4A) and for the average of all clots in a given condition (Fig. 4-4B). With each clot
graphed, there was a noticeable correlation (R2 = 0.67) between platelet FI and global
aggregate contraction (Fig. 4-4A). However, there was some deviation in individual clots;
when the average of each condition was taken, the correlation improved considerably (R2
= 0.87; Fig. 4-4B). This demonstrated an observable correlation between platelet FI and
global aggregate (CD61+) contraction.
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Figure 3-5. ASA limits local platelet contraction, while 2-MeSAMP and MRS-2179 have no effect.
We performed a meta-analysis of data from Figure 3-3B by segregating data into different component
conditions. Each of the 4 conditions with ASA and each of the 4 conditions without ASA were averaged
and compared (A); the same was done for 2-MeSAMP (B) and MRS-2179 (C). (N = 3 donors, n = 24 clots
for each panel; *p<0.05, **p<0.01, ***p<0.001)

ASA limits local aggregate contraction, while 2-MeSAMP and MRS-2179 have no
effect
In Figure 3-3B, conditions that had ASA present tended to have reduced local
aggregate contraction. To determine the significance ASA had on limiting local aggregate
contraction, we grouped all conditions that either had or did not have ASA (Fig. 3-5A), 2MeSAMP (Fig. 3-5B), or MRS-2179 (Fig. 3-5C). When conditions were separated based
on the presence or absence of 2-MeSAMP, there was no significant difference in local
aggregate contraction (Fig. 3-5B). The same was true for MRS-2179 (Fig. 3-5C),
suggesting ADP inhibition had no significant effect on local aggregate contraction.
However, when conditions were separated based on the presence or absence of ASA,
there was a significant difference (p<0.0001) in local aggregate contraction, with ASA
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conditions showing reduced contraction relative to conditions without ASA (Fig. 3-5A).
This suggests that TXA2 inhibition may have had a limiting effect on local aggregate
(CD61+) contraction.

Figure 3-6. Schematic of clot development and contractile processes under control conditions (A) and
with ADP/TXA2 inhibitors present (B).

3.4

Discussion
Clot contraction is a key element of clot resolution, and platelet contractility plays a

significant role in contributing to contraction. Using our microfluidic device, we were
able to evaluate clot contraction due from platelet contractility on a global and local basis
in the presence of ADP and TXA2 inhibitors. To our knowledge, this is the first report
evaluating platelet contractility in the presence of ADP and TXA2 inhibitors using
microfluidics at a venous shear rate. We found that ASA, 2-MeSAMP, and MRS-2179
had an additive effect in limiting CD61+ platelet deposition, but not with P-selectin+
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platelets. P-selectin+ platelet aggregates had limited global and local contraction
regardless of ADP or TXA2 inhibition. On the other hand, ADP and TXA2 inhibition
seemed to have an additive effect on limiting global contraction of CD61+ platelet
aggregates, while TXA2 inhibition, not ADP inhibition, limited local CD61+ aggregate
contraction. Lastly, we found that platelet FI correlates with global CD61+ aggregate
contraction.
We have summarized these findings in Figure 3-6, which illustrates our
understanding of clot contraction in the presence or absence of ADP and TXA2
inhibition. When there was no ADP or TXA2 inhibition, we saw significant CD61+
platelet deposition and P-selectin display at 7.5 min, and then after 7.5 min of flow
cessation, CD61+ platelets contracted locally, which contributed to global contraction of
CD61+ platelet aggregates. For P-selectin, there was limited local and global contraction.
When ADP and TXA2 inhibitors were present, we saw reduced CD61+ platelet
deposition and reduced P-selectin+ platelet deposition. We still saw local CD61+
aggregate contraction (which was reduced by TXA2 inhibition), but because there was
significantly less CD61+ platelets when ADP and TXA2 inhibitors were present, they
were not able to affect global CD61+ aggregate contraction as much.
Our finding that P-selectin+ platelets had limited contractility is in agreement
with previous findings [2,16,65]. In the core/shell model of clot heterogeneity, Pselectin+ platelets in the core are more closely packed, while P-selectin(-) platelets in the
shell are loosely packed [2,16,65]. It would follow then that P-selectin+ platelets would
not be able to contract as much if they are closely packed, compared to CD61+ platelets
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in the shell region that are loosely connected and have greater ability to physically
contract. We also observed that ADP inhibition and TXA2 inhibition each reduced
CD61+ platelet deposition and P-selectin+ platelets in clots. However, we found that the
combination of ADP and TXA2 inhibition further reduced CD61+ platelet deposition,
while it did not further reduce P-selectin display. This may demonstrate that ADP and
TXA2 inhibition had a greater effect on P-selectin(-) shell platelets than on P-selectin+
core platelets. Additionally, P-selectin+ platelets are closer to collagen than shell
platelets; ADP and TXA2 inhibition may no longer be effective at reducing P-selectin
after a certain point, possibly due from collagen-induced P-selectin display.
We found that ASA limits local CD61+ platelet contraction, while 2-MeSAMP
and MRS-2179 did not. While the pharmacological mechanism for this difference should
be studied further, it was likely not due from differences in clot morphology, since clots
of varying degrees of platelet deposition were included in both +ASA and -ASA
conditions (Figure 3-1A and B), and there was a consistent decrease in % local platelet
contraction in conditions with ASA compared to conditions without ASA (Figure 3-3B).
In terms of global CD61+ platelet contraction, we found that ADP and TXA2 inhibition
reduced platelet contraction, which is in agreement with previous findings [49]. We
observed a trend where greater platelet deposition generally resulted in greater global
platelet contraction, which we confirmed in our data (R2 = 0.87; Fig. 3-4B). While a
greater number of platelets can physically limit the ability of a clot to contract, the more
platelet-platelet interactions there are, the greater contractile connectivity in the clot. In
clots where ADP and TXA2 severely limited CD61+ platelet deposition, there were
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reduced platelet-platelet interactions, and as we saw in our results, ultimately less global
contraction.
It is important to note this study was limited to evaluating platelet-driven
contraction; in addition to platelets, leukocytes and red blood cells (RBCs) can also be
found in blood clots. It has been shown that monocytes can aid platelet-driven contraction
[66]. In the case of ischemic stroke patients, thrombi with greater leukocyte composition
were associated with increased fatality [67]. In contrast to leukocytes, RBCs impair clot
contraction [40]. RBCs contracting within a clot have a polyhedron shape, forming a
compact array of polyhedral structures [51,68]. In patients with sickle cell disease,
impaired clot contraction is due from decreased RBC deformability [69]. Future studies
should focus further on evaluating the roles of leukocytes and RBCs on global and local
aggregate contraction.
Fibrinogen plays an important role in platelet aggregation. Fibrinogen binds
platelets via integrin αIIbβ3, which allows for platelet-platelet interactions. However,
fibrinogen has been shown to limit clot contraction [40]. It has also been shown that
ischemic stroke patients had higher fibrinogen levels compared to healthy subjects [55].
While fibrinogen was not extensively investigated in this study, it should be studied
further for its limiting effect on clot contraction at higher concentrations [40].
Impaired clot contraction has been implicated as a complicating factor in a
number of conditions. Clinical correlations based on patient data suggest that impaired
clot contraction may be a risk factor for ischemic stroke [55]. Reduced clot contraction
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has also been seen in patients with venous thromboembolism [53,54].
Hyperhomocysteinemia, or increased homocysteine levels, causes excessive platelet
activation and impairs contraction, making clots larger and more obstructive [70].
Reduced clot contraction in blood of systemic lupus erythematous patients impairs blood
flow and could be a risk factor for increased thrombosis [71]. In sickle cell patients, clots
have impaired contraction due to pathological stiffening of RBCs in blood clots [69].
Reduced clot contraction is a pathological risk factor for and is correlated with a number
of pro-thrombotic conditions. This study and future studies focused on better
understanding clot contraction will help in our ability to better mitigate and resolve these
types of pro-thrombotic conditions.
These results demonstrate a necessary balance in platelet deposition and aggregate
contraction. For hemostasis to be properly maintained, hyper-activation of platelets must
be limited to prevent thrombosis or embolization, but there also must be sufficient
platelet deposition to allow for a clot to form and subsequently contract. ADP and TXA2
inhibitors seek to alter this balance by preventing thrombosis, but too much inhibition can
result in bleeding. Part of the reason for this potential bleeding, from our results here,
could be due from ADP and TXA2 inhibitors’ ability to limit clot contraction and clot
resolution. Understanding the fundamental mechanisms behind how these inhibitors
affect clot contraction has potentially significant clinical benefits in deciding how to treat
patients who may require anti-platelet agents.
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CHAPTER 4: THE EFFECT OF ANTI-GPVI FAB E12 ON PLATELET
DEPOSITION AND PHOSPHATIDYLSERINE EXPOSURE

4.1

Introduction
Glycoprotein VI (GPVI) is a known platelet-specific receptor that binds collagen

and subsequently activates platelets [72,73]. Upon initial vessel injury, collagen becomes
exposed, allowing for GPVI binding and strong signaling in platelets. This interaction
between collagen and platelets is crucial for primary activation and aggregation [74,75],
with GPVI as a mediator for this process [76,77]. However, recent reports demonstrate
that GPVI may bind with other ligands as well, such as fibrin [72,78]. Thus, GPVI may
have a secondary role in clot formation after collagen is covered by platelets, such as
mediating platelet recruitment during secondary deposition [79] or contributing to clot
contraction caused by fibrin [80].
There are a number of different previous studies that have evaluated GPVIdeficiency in a number of different contexts: using different anti-GPVI antibodies [80–
85], indirect inhibition of GPVI on human platelets [86,87], in vivo GPVI-deficient
mouse models [88,89], in vitro models with GPVI-deficient mouse blood [72,81–83],
models with GPVI-deficient human blood [83,90], testing different surface activating
materials [80,90], human atherosclerotic plaque material [80,85], microfluidic venous
valve model [84], among others. Dubois, et al. showed a significant decrease in platelet
accumulation for GPVI-deficient mouse platelets compared to WT when thrombin was
inhibited [88]. However, Mangin, et al. showed that when thrombin is present, this
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decrease in platelet accumulation is abolished, leading to the conclusion that thrombin is
able to overcome GPVI-deficiency and allow thrombus formation to occur normally [89].
Recent research has been focused on developing a specific inhibitor to GPVI [76].
In previous studies, inhibition of GPVI was mostly achieved through blocking of kinases
in subsequent activation pathways, such as inhibition of Src Family Kinases (SFK),
spleen tyrosine kinase (Syk) and Bruton’s tyrosine kinase (BTK) [86,91–93]. Some of
these inhibitors are irreversible, which serves as a “knockout” condition for GPVI.
However, this method has its own limitations. These kinases serve more than one role
and function downstream of different platelet receptors [94,95]. The recent development
of direct inhibition of GPVI, mostly led by Watson [91] and Nieswandt [75,77], alleviates
these concerns. Additionally, evaluation of the effects of GPVI inhibition under flow
more accurately mimics in vivo dynamics compared to static in vitro assays [76]. To
differentiate the role of GPVI at different stages of clot formation under flow, the
inhibition of GPVI can be controlled in a microfluidic assay, which is difficult to achieve
in vivo and in aggregometry assays [74,86].
Therefore, we aimed to investigate the role of a novel anti-GPVI Fab (the Fab
fragment of human GPVI blocking antibody (clone E12)) developed by the Nieswandt
research group under hemodynamic conditions using our microfluidic assay. GPVI
interaction with fibrin(ogen) has previously been reported to play a role in arterial
conditions [80,83]. Lehmann, et al. developed a venous thrombosis model with
dimensional similarity to venous valves, showing that GPVI is essential for platelet
activation and subsequent thrombus propagation [84]. Thus, GPVI has been shown to
52

play significant roles in both arterial and venous thrombus formation [96]. However, we
limited this study to evaluating E12 under venous conditions rather than arterial, as
arterial shear rates can cause clot heterogeneity and increased risk of embolization in our
microfluidic model. Studies conducted in this in vitro microfluidic assay have
demonstrated that a perfusion-switch experimental design can be used to rapidly change
conditions [87], fluids, or shear [97] during experiments, and to study the characteristics
of clots at different stages of coagulation. We also utilized confocal microscopy to
validate our in vitro microfluidic assay results.
We found that GPVI played a role in primary and secondary platelet deposition, as
well as fibrin polymerization, but this role was modulated by the presence of thrombin
generation. With thrombin present, anti-GPVI Fab did not limit platelet deposition, as
thrombin was the most likely cause of normal platelet deposition. With our perfusionswitch experimental design, we showed that the initial layer of platelets was crucial for
clot development, as switching from control to anti-GPVI WB had little to no effect on
the clot, while switching from anti-GPVI WB to control WB restored normal clot
development. Together, our results demonstrate a deeper understanding of the role GPVI
plays in primary and secondary deposition, fibrin polymerization, and PS exposure.
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4.2

Materials and Methods

Materials
Reagents were obtained as follows: anti-human CD61 antibody (BD Biosciences,
San Jose, CA. Cat#: 555754), Alexa Fluor anti-human CD62P (P-Selectin) Antibody
(BioLegend, San Diego, CA. Cat#: 304918), Alexa Fluor 546–conjugated human
fibrinogen, Alexa Fluor 488-conjugated annexin V (ThermoFisher Scientific, Waltham,
MA. Cat#: A13201), Dade Innovin prothrombin time (PT) reagent (Siemens, Malvern,
PA. Cat#: B4212-40), collagen (type I; Chrono-Log, Havertown, PA. Cat#: 385),
Sigmacote® (Millipore Sigma, Burlington, MA. Cat#: SL2-100ML), H-Gly-Pro-ArgPro-OH (GPRP; Millipore Sigma, Burlington, MA. Cat#: 03-34-0001), GR-144053
(Tocris Biosciences, Bristol, UK. Cat#: 1263), Phe-Pro-Arg-chloromethylketone
(PPACK, Haematologic Technologies, Essex Junction, VT. Cat#: FPRCK-01) and corn
trypsin inhibitor (CTI, Haematologic Technologies, Essex Junction, VT. Cat#: CTI-01).
The Fab fragment of human GPVI blocking antibody (clone E12) was a generous gift
from N. Stefano and Dr. B. Nieswandt from University of Würzburg.
Preparation and characterization of collagen/TF surface
Glass slides were rinsed with ethanol, then deionized water, and dried with
filtered air. Sigmacote® was used to create a hydrophobic surface on the glass. A volume
of 5µL of fibrillar collagen was perfused through a patterning channel (250 µm wide × 60
µm high) of a microfluidic device to create a single 250 µm-wide strip of fibrillar
collagen for all experiments, as previously described [47,64]. For experiments without
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thrombin interaction, collagen was rinsed and blocked with 20 µL 0.5% bovine serum
albumin (BSA) buffer. For experiments that study the effect of thrombin, lipidated TF
was absorbed to the collagen surface by perfusing 5 µL of Dade Innovin PT reagent (20
nM stock concentration), rinsed and blocked with 20 µL 0.5% BSA, then incubated for
30 min without flow, as previously described [47,64].
Blood collection and preparation
Blood was obtained via venipuncture into a syringe containing high concentration
of CTI (40 µg/mL) from healthy donors who self-reported as free of alcohol use for at
least 72 hours and medication for at least a week prior to blood collection. All donors
provided informed consent under approval of the University of Pennsylvania Institutional
Review Board. Blood was treated with anti-human CD61 antibody (1:50 v/v in whole
blood) and Alexa Fluor-conjugated human fibrinogen (1.5 mg/mL stock solution, 1:80
v/v in whole blood) immediately after blood collection for platelet labeling and fibrin
labeling, respectively. Annexin V (1:80 v/v in whole blood) was added for PS labeling.
Anti-GPVI Fab was added to collected whole blood at a final concentration of 10 µg/mL
(stock solution 1 mg/mL, dissolved in biology grade water). GPRP (5 mM final
concentration in blood) and GR-144053 (1 µM final concentration in blood) were both
dissolved in Millipore water. All experiments were initiated within 5 min after
phlebotomy.
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Microfluidic clotting assay on collagen surfaces with or without TF
An 8-channel polydimethylsiloxane (PDMS) flow device was vacuum-sealed
perpendicularly to collagen/TF surfaces forming 8 parallel-spaced prothrombotic patches
(250 × 250 µm), as previously described [47,64]. The microfluidic device channel height
used was 120 µm to prevent occlusion, with an initial wall shear rate of 100 s-1. CTItreated blood was perfused across the 8 channels by withdrawal through a single outlet.
Drug-treated blood was added to the inlet reservoir without stopping flow, thus providing
a rapid change in perfusion pharmacology within < 15 sec without hemodynamic
crosstalk between channels during the perfusion switch. All clotting events were initiated
simultaneously in the microfluidic device on the collagen strip. Initial wall shear rate was
controlled by a syringe pump (Harvard PHD ULTRA / Harvard PHD 2000; Harvard
Apparatus, Holliston, MA) connected to the outlet on the flow device. Platelet, fibrin,
and/or PS activities were monitored simultaneously by epifluorescence microscopy
(IX81; Olympus America Inc., Center Valley, PA) at 10X magnification. For each set of
experiments, blood samples from N≥3 donors were taken, unless otherwise specified.
Additionally, each clot was extremely well localized on the 250 µm x 250 µm collagen
patch and contained tens of thousands of platelets, ideal for obtaining whole clot
fluorescence intensities (i.e. total clot mass) with time. Images were captured with a
charged coupled device camera (Hamamatsu, Bridgewater, NJ) and were analyzed with
ImageJ software (National Institutes of Health). To avoid side-wall effects, fluorescence
values were taken only from the central 75% of the channel.
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Confocal Microscopy
To determine the 3-dimensional orientation of platelets, fibrin, and PS exposure,
we utilized confocal microscopy to develop images of the clots in the microfluidic
device. For confocal images, all clots imaged were formed under high CTI WB perfused
over collagen/TF (100s-1) for 7.5 min. After 7.5 minutes of WB perfusion, WB was
switched with BSA (+ 5mM CaCl2) and perfused for about 2 minutes to clear out any
remaining blood in the channels. After BSA perfusion, any remaining BSA (+ 5mM
CaCl2) in the wells was replaced with 4% paraformaldehyde (+ 5mM CaCl2) and
perfused for about 2 minutes to fix clots and prevent contraction. After 2 minutes of
perfusion with 4% paraformaldehyde (+ 5mM CaCl2), perfusion was stopped and devices
were transferred to the confocal microscope, with clots still maintained in the 8-channel
microfluidic device. Z-stack images were taken of fixed clots using the Leica TCS SP8
laser scanning confocal microscope at the CDB Microscopy Core at the University of
Pennsylvania. Images were compiled to form a 3D rendering of a clot endpoint in
ImageJ.
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4.3

Results

Figure 4-1. Inhibition of GPVI shows significant decrease in PS exposure.
High CTI WB with and without anti-GPVI Fab was perfused over collagen/TF at 100s-1 for 10.5 minutes.
CD61, fluorescent fibrinogen, and annexin V fluorophores were added to label platelets (A), fibrin (B), and
PS exposure (C), respectively, with images taken at 270s and 630s. Fluorescence intensities for platelets
(D), fibrin (E), and annexin V (F) were measured throughout the course of the experiments. (A.U. =
arbitrary units)
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Anti-GPVI Fab inhibits fibrin polymerization and PS exposure in clot development
when added at t=0
To investigate the role of anti-GPVI in PS exposure, we perfused CTI-treated WB
± anti-GPVI Fab over collagen/TF (100s-1) looking at platelet, fibrin, and
phosphatidylserine (PS) fluorescence. We observed normal platelet deposition in control
and limited platelet deposition from the initial stages of clot development with anti-GPVI
Fab present (Fig. 4-1A, 4-1D), and normal fibrin polymerization in control and limited
fibrin polymerization with anti-GPVI Fab (Fig. 4-1B, 4-1E). Compared to control, we
saw essentially no PS exposure when anti-GPVI Fab is present (Fig. 4-1C, 4-1F).
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Figure 4-2. Decrease in annexin V in the presence of anti-GPVI is due from anti-GPVI, not limited
platelet deposition or fibrin polymerization.
High CTI WB with control (HBS), GR-144053, GPRP, or anti-GPVI Fab, was perfused over collagen/TF
at 100s-1 for 10.5 minutes. CD61, fluorescent fibrinogen, and annexin V fluorophores were added to label
platelets (A), fibrin (B), and PS exposure (C), respectively, with images taken at 270s and 630s.
Fluorescence intensities for platelets (D), fibrin (E), and annexin V (F) were measured throughout the
course of the experiments. (A.U. = arbitrary units)
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We then wanted to validate that the limited PS exposure in anti-GPVI channels
was indeed due from anti-GPVI Fab rather than limited platelet deposition or fibrin
polymerization. To do this, we compared annexin V FI in the presence of anti-GPVI Fab,
GR-144053, or GPRP. GR-144053 inhibits integrin αIIbβ3, thereby preventing plateletplatelet interactions and results in a platelet monolayer [98]. We perfused CTI-treated
WB ± GR-144053, GPRP, or anti-GPVI Fab over collagen/TF at an initial wall shear rate
of 100s-1. Platelet deposition was normal in control and GPRP, while there was reduced
platelet deposition in anti-GPVI, and only a platelet monolayer in GR-144053 (Fig.4-2A,
4-2D). Fibrin levels were normal in control and GR-144053, while there was little to no
fibrin in GPRP or anti-GPVI (Fig. 4-2B, 4-2E). We observed slightly increased PS
exposure with GR-144053 or GPRP compared to control, while anti-GPVI Fab once
again had essentially no PS exposure (Fig. 4-2C, 4-2F).
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Figure 4-3. Effects of anti-GPVI Fab require its presence from the initiation of clot development in
the presence of thrombin.
High CTI WB with or without anti-GPVI Fab was perfused over collagen/TF at 100s-1 for 10.5 minutes.
The two middle channels started with control WB perfusion, with a switch to anti-GPVI WB at either 30s
or 90s. CD61, fluorescent fibrinogen, and annexin V fluorophores were added to label platelets (A), fibrin
(B), and PS exposure (C), respectively, with images taken at 270s and 630s. Fluorescence intensities for
platelets (D), fibrin (E), and annexin V (F) were measured throughout the course of the experiments. (A.U.
= arbitrary units)
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Anti-GPVI Fab has little to no effect on platelet deposition, fibrin polymerization, or
PS exposure when added after t=0s
We next investigated the effect of anti-GPVI Fab addition at different time points
to determine if early or later inhibition of GPVI affected PS exposure. We perfused CTItreated WB under 4 different conditions: (1) control WB with no switch, (2) control WB
at 0s, followed by a switch to anti-GPVI WB at 30s, (3) control WB at 0s, followed by a
switch to anti-GPVI WB at 90s, and (4) anti-GPVI WB with no switch. We found that
platelet deposition was similar in conditions (1), (2), and (3) throughout the experiment
(Fig. 4-3A, 4-3D), illustrating that anti-GPVI Fab had little to no effect on platelet
deposition when control blood was present from the start. Fibrin polymerization was also
similar among conditions (1), (2), and (3) throughout the experiment (Fig. 4-3B, 4-3E),
also illustrating that anti-GPVI Fab had little to no effect on fibrin polymerization when
control blood was present initially. In terms of PS exposure, annexin V binding was fairly
similar between conditions (1), (2), and (3), while there was essentially no PS exposure in
anti-GPVI Fab at t = 0s condition (4) (Fig. 4-3C, 4-3F). These results demonstrate that
when control WB was initially present to all platelet interactions with collagen, GPVI
signaling, and thrombin generation, the addition of anti-GPVI Fab at later time points had
little to no effect on platelet deposition, fibrin polymerization, and PS exposure.
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Figure 4-4. Effects of anti-GPVI Fab on clot development are reversible.
High CTI WB with or without anti-GPVI Fab was perfused over collagen/TF at 100s-1 for 10.5 minutes.
The two middle channels started with anti-GPVI WB perfusion, with a switch to control WB at either 90s
or 270s. CD61, fluorescent fibrinogen, and annexin V fluorophores were added to label platelets (A), fibrin
(B), and PS exposure (C), respectively, with images taken at 270s and 630s. Fluorescence intensities for
platelets (D), fibrin (E), and annexin V (F) were measured throughout the course of the experiments. The
green arrows in FI plots indicate when 90s switches occur and black arrows indicate when 270s switches
occur (A.U. = arbitrary units)
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The effects of anti-GPVI Fab are reversible for platelet deposition, fibrin
polymerization, and PS exposure when switched to control blood
Lastly, we wanted to evaluate the effect of switching from anti-GPVI Fab-treated
WB back to control WB lacking Fab. We perfused CTI-treated WB again under 4
conditions: (1) control WB with no switch, (2) anti-GPVI WB at t=0s, followed by a
switch to control WB at 90s, (3) anti-GPVI WB at t=0s, followed by a switch to control
WB at 270s, and (4) anti-GPVI WB with no switch. Platelet deposition in condition (1)
formed normally, while there was limited platelet deposition in anti-GPVI condition (4)
(Fig. 4-4A, 4-4D). In the switch conditions, both conditions initially had limited platelet
deposition, but after about 180s post-switch, there was a significant increase in platelet
levels in both conditions relative to condition (4). There were statistical differences in
final fluorescence values between conditions (2) and (4) (p = 0.0032) and between
conditions (3) and (4) (p=0.0014). After platelets levels began increasing in the switch
channels, the platelet clot morphology was restored back to control conditions. In terms
of fibrin fluorescence, we again observed normal fibrin formation in condition (1) and
essentially no fibrin formation in condition (4), as expected and as previously shown. In
the switch channels, there was essentially no fibrin polymerization throughout nearly the
entirety of the experiment, except at the very end where there was a slight increase in
fibrin (Fig. 4-4B, 4-4E). Even still, these slight increases were found to be statistically
significant compared to anti-GPVI; there were statistical differences in final fibrin
fluorescence between conditions (2) and (4) (p=0.0009) and between conditions (3) and
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(4) (p=0.017). Lastly, annexin V levels were normal in condition (1) and essentially
negligible in condition (4), again in agreement with previous results. In the switch
conditions, annexin V was negligible initially, as expected, and then eventually increased
after the switch to control WB (Fig. 4-4C, 4-4F). Again, there were statistical differences
in final annexin V fluorescence between conditions (2) and (4) and between conditions
(3) and (4) (both p<0.0001). There was again an approximate 180s time lag between the
switch and when annexin V levels began increasing in both conditions. This is in line
with the platelet restoration time lag.
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Figure 4-5. Annexin V and anti-GPVI Fab have additive effect on limiting platelet deposition.
High CTI WB, with and without annexin V and anti-GPVI, was perfused over collagen/TF at 100s-1 for
10.5 min. CD61, fluorescent fibrinogen, and annexin V fluorophores were added for platelets (A), fibrin
(B), and PS exposure (C). Annexin V was not added in channels with (-annexin V). Representative images
were taken at the end of the experiment (10.5 min). Fluorophores were measured throughout the course of
the experiment for platelet fluorescence (D) and fibrin fluorescence (E). Representative data are from 2
individual donors (N = 2) and 4 individual clots (n = 4). (A.U. = arbitrary units).
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The combination of annexin V and anti-GPVI Fab significantly impedes platelet
deposition in CTI-treated WB perfused over collagen/TF
We wanted to further evaluate the effect of anti-GPVI Fab and annexin V on PS
exposure in clot development. Annexin V binds to exposed PS on the surface of platelets;
as a result, this annexin V binding may prevent PS on the platelet surface from fully
contributing to platelet procoagulant activity, and ultimately delaying and/or lowering
fibrin generation [99]. We have previously shown this to be this case in our assay, where
annexin V contributed to a delay in fibrin formation compared to when annexin V was
absent [52]. To investigate the effect of annexin V in the presence of anti-GPVI Fab on
clot development, we perfused CTI-treated WB with anti-GPVI alone, with annexin V
alone, or with both anti-GPVI Fab and annexin V, over collagen/TF (100 s-1) (Fig. 4-5AC). Results showed that anti-GPVI or annexin V alone had almost no effect on platelet
deposition (Fig. 4-5A, 4-5D). Annexin V channels had a slight delay and decrease in
fibrin polymerization (in agreement with ref. [52]), while anti-GPVI Fab channels
showed inhibition of fibrin polymerization (Fig. 4-5B, 4-5E). However, when both antiGPVI Fab and annexin V were present, there was a striking decrease in platelet
deposition (Fig. 4-5A, 4-5D). Fibrin deposition was also reduced in the presence of both
anti-GPVI Fab and annexin V, resulting in levels slightly lower than anti-GPVI Fab alone
(Fig. 4-5D), all consistent with strong collagen signaling via GPVI along with thrombin
enhancing the procoagulant activity of platelets.
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Figure 4-6. Representative 3D images of clot end point.
Z-stack images were taken of preserved clots on a confocal microscope to determine the distribution of
platelets (red), fibrin (green) and annexin V (blue). (A) Bottom view of clot (on coverslip). (B) Top view of
clot. (C) Clot side view. (D) Clot outlet view. (E) Single z plane image of clot with orthogonal slices
pointed out (yellow lines). (F) Vertical orthogonal slice from wall to wall of microfluidic device channel.
(G) Horizontal orthogonal slice from clot inlet to clot outlet.
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Confocal microscopy confirms fibrin and PS exposure are localized to collagen
surface, while platelet deposition occurs throughout the clot thickness
Confocal images show an example clot from the bottom view (Fig. 4-6A), top view
(Fig. 4-6B), side view (Fig. 4-6C), and outlet view (Fig. 4-6D). These images illustrate
that fibrin and annexin V were predominantly localized near the collagen surface, while
platelets were distributed throughout the clot, most clearly visible at the top layer of the
clot. We also took example orthogonal slices of the clot (Fig. 4-6E-G) to further illustrate
the localization of fibrin and PS exposure at the collagen surface.

4.4

Discussion
We performed a series of in vitro experiments with human blood using a novel,

direct GPVI inhibitor to demonstrate the role GPVI plays in primary and secondary
platelet deposition and fibrin polymerization. We observed that anti-GPVI Fab
significantly reduced annexin V fluorescence nearly to background levels. To confirm
this was due from anti-GPVI Fab rather than reduced platelet aggregation or fibrin
inhibition, we compared the annexin V signals of anti-GPVI, GR-144053, and GPRP in
the presence of thrombin. We saw that platelet monolayers (via treatment with GR144053) and fibrin inhibition (via treatment with GPRP) resulted in similar or increased
annexin V fluorescence, while annexin V fluorescence in the anti-GPVI condition
remained near background levels. This demonstrated the potent effect of anti-GPVI and
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annexin V in limiting PS exposure. To better understand this synergistic effect, we
performed two experiments to evaluate annexin V fluorescence: (1) switching from
control blood to anti-GPVI blood, and (2) switching from anti-GPVI blood to control
blood. When control blood was present at the beginning of the experiment, platelet
deposition, fibrin polymerization, and PS exposure occurred normally, even when antiGPVI Fab was present as early as 30s. When anti-GPVI blood was present at the
beginning of the experiment, but there was a switch to control blood, platelets, fibrin, and
annexin V slowly began to increase after the switch. This demonstrated that the effects of
anti-GPVI Fab were reversible, while anti-GPVI Fab was not effective (in the presence of
thrombin) when it first became present after control clotting had already been initiated.
There was a synergistic effect of inhibition of GPVI and inhibition of exposed PS
on lowering platelet deposition in clot development. Increased PS exposure in GR144053 compared to control further demonstrated the significance of collagen in
stimulating PS exposure, since essentially all platelets in GR-144053 were bound and
stimulated via collagen. Increased PS exposure in the presence of GPRP compared to
control demonstrated the role of freely available thrombin to contribute to PS exposure,
and we have previously shown this before [52]. Therefore, when collagen interactions
were inhibited by anti-GPVI Fab and freely available thrombin was reduced by annexin
V, it follows that there was very little measurable PS exposure. Our results support the
significant role for thrombin generated via PS exposure in stimulating platelet deposition
and continued buildup when GPVI is inhibited. Since annexin V binds exposed PS on the
platelet surface [100,101], and PS allows for formation of the prothrombinase complex
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for conversion of prothrombin to thrombin catalyzed by Factor Xa [102], annexin V
binding to PS may have reduced the generation of thrombin at the beginning of the clot
growth, thus resulting in limited platelet stimulation via thrombin. Blocking collagen
binding and inhibiting thrombin generation are both crucial for attenuating subsequent
platelet deposition.
In our perfusion-switch experiments with annexin V present, our results in Figure
4-4 suggest that the time lag between the switch and increase in platelet fluorescence may
have consisted of the removal of GPVI-inhibited platelets with control platelets. In
addition, the time lag for fibrin formation to be restored took longer than for platelet
deposition, which is logical since platelet deposition precedes fibrin polymerization in
control conditions, and is in agreement with thrombin kinetics [45,80]. These results
suggest switching from anti-GPVI WB to control WB nearly allowed for clot restoration
in terms of platelet deposition and morphology, fibrin polymerization, and PS exposure.
This was not the case when control WB was switched to anti-GPVI WB, where we saw
platelet deposition, fibrin polymerization, and annexin V remained similar to control
throughout the experiment (Fig. 4-3).
Many of our findings are consistent with previous studies investigating GPVI
deficiency/inhibition. Munnix, et al. studied the effects of an anti-GPVI JAQ1 Fab on
platelet deposition and PS exposure in PPACK-treated WB over collagen, and in citrated
mouse blood (+CaCl2 +TF) over collagen at 1000s-1 [81]. They also observed a
significant decrease in annexin V exposure with JAQ1, similar to what was observed with
E12 (Fig. 4-1). However, they also observed a decrease in platelet deposition with JAQ1
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in the presence of thrombin [81], while we did not see this change in platelet deposition
when E12 was added without annexin V present (Fig. 4-5). The reason for this should be
studied further to better understand why E12 does not cause a decrease in platelet
deposition in the presence of thrombin.
We have shown that with thrombin present, anti-GPVI did not limit platelet
deposition, as thrombin was the most likely cause of normal platelet deposition. With our
perfusion-switch experimental design, we showed that the initial layer of platelets was
crucial for clot development, as switching from control to anti-GPVI WB had little to no
effect on the clot, while switching from anti-GPVI WB to control WB restored normal
clot development. Together, our results demonstrate a deeper understanding of the role
GPVI plays in primary and secondary platelet deposition, fibrin polymerization, and PS
exposure.
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CHAPTER 5: FUTURE WORK

5.1

Further investigation of PS+ platelet sorting in clot development
There are a number of further studies that can and should be performed to further

our understanding of PS+ platelet sorting in clots. First, in vivo studies would be
particularly useful to see how different anti-coagulant agents may affect this PS+ platelet
sorting phenomenon. Nechipurenko, et al. [28] performed some in vivo studies that
observed localization of procoagulant platelets at the clot periphery, but these were
limited to mostly images as opposed to quantitative data. Testing anti-coagulants like
direct thrombin inhibitors or FXa inhibitors, or accelerating fibrinolysis by exogenous
addition of tPA, in an in vivo mouse model would be useful to see if our findings here are
robustly observable.
Additionally, studying the effects of blebbistatin in vitro and in vivo would be
useful. Blebbistatin is a non-muscle myosin II inhibitor [103,104], which limits internal
platelet contraction. Samson, et al. [30] showed that blebbistatin had a potent limiting
effect on clot contraction over a 120-minute period. In our microfluidic model, the time
frame for clot development is generally from 15-20 minutes, which could make it
difficult to observe the effects of blebbistatin in a relatively shorter time frame. However,
it could be interesting to see how clots further develop and contract over time once flow
has stopped. In future experiments, perfusing CTI-treated WB with and without
blebbistatin for 15 minutes, followed by a 2 hour stop flow period to observe contraction,
would be useful to determine if blebbistatin prevents PS+ platelet sorting, which would be
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consistent with the observation by Nechipurenko, et al. that non-muscle myosin-deficient
mouse blood does not display PS+ platelet sorting [28].

Figure 5-1. Pearson correlation coefficients of annexin V fluorescence between final clot image (at 15
minutes) and clot image at varying time points among all conditions tested.
In our experiments, we used Pearson correlation coefficients of annexin V at 9 minutes and 15 minutes.
Here, we graphed Pearson correlation coefficient values between the final clot image of annexin V (at 15
minutes) compared to images of annexin V at different time points. Thus, the Pearson correlation
coefficient of 9 minutes and 15 minutes would correspond to a time gap of 360s (on the x-axis). However,
Pearson correlation coefficients may be chosen between the final image (at 15 minutes) and an image at
some other time point (other than 9 minutes). This data here illustrates what those Pearson correlation
coefficients would be for PPACK experiments (A), GPRP experiments (B), tPA experiments (C), and
PPACK control (no TF) experiments (D).
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Lastly, further optimization of the autocorrelation and Pearson correlation metrics
could be useful to further distinguish more minute differences in PS sorting that may be
observed. For example, Pearson correlation coefficients can be measured at varying time
points, as illustrated in Figure 5-1. Here, we measured the Pearson correlation coefficient
between 15 minutes and each other image throughout the time course of the experiment.
You can see that as the difference in time between images increased, the Pearson
correlation decreased, which indicates a change in PS fluorescence distribution.
However, we can see for +PPACK, +GPRP, and +tPA conditions, their Pearson
correlation coefficient decreased at a much quicker pace compared to control conditions
(-PPACK, -GPRP, and -tPA) as the time between images increased. This type of analysis
helped us choose a Pearson correlation coefficient of 9 minutes vs. 15 minutes in our
analysis, as the differences in Pearson correlation coefficients between ±PPACK,
±GPRP, ±tPA conditions were well pronounced.
We could perform a similar analysis for the autocorrelation metric. Autocorrelation
metric values were calculated using a truncated matrix of values (Supp. Fig. S2-3);
however, the exact size of this truncated matrix can vary. Further analyses of an optimal
truncation size could help to further optimize the autocorrelation metric as a tool to
measure heterogeneities in clots. We could also investigate cross correlation values
between CD61 fluorescence images and annexin V among different conditions. As PS+
platelets move to the periphery of platelet masses with fibrin inhibited, conditions with
fibrin inhibition may have greater cross correlation between CD61 and annexin V
compared to conditions with fibrin present. This would be another useful way to
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potentially illustrate the differences between PS sorting in the presence and absence of
fibrin.

5.2

Evaluating the effects of secondary platelet inhibition on clot contraction
To expand upon our investigation of ADP and TXA2 inhibition on clot contraction,

there are a number of additional studies that could be performed. First, studying a wider
variety of ADP and TXA2 inhibitors, or other secondary platelet aggregation inhibitors,
would be useful to further analyze different methods of preventing platelet aggregation,
and global and local aggregate contraction. Next, studying ADP and TXA2 inhibition in
the presence of thrombin and fibrin would be especially important. While our focus here
was trying to understand how platelet-platelet interactions affect clot development, under
normal conditions, fibrin formation occurs. It is important to understand how inhibition
of secondary platelet aggregation affects local and global clot contraction when fibrin is
present. To do so, we can perfuse CTI-treated WB ±ADP and TXA2 inhibitors over
collagen/TF to investigate contraction with thrombin and fibrin present. We can also
perfuse CTI-treated WB + GPRP ±ADP and TXA2 inhibitors over collagen/TF to
investigate contraction with thrombin present, but fibrin still inhibited.
In the future, it would also be insightful to test patient blood to determine how
contraction occurs in non-healthy donor blood. Patients who are on anti-platelet or anticoagulant regimens with a range of dosages would be interesting to analyze. Our
observations thus far have been based on data obtained from healthy donors who are
medication-free. Ultimately though, patient blood (inhibiting ADP and TXA2
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production) would be especially important to see how their blood contracts. It would also
be interesting to apply our global and local aggregate contraction measurements to blood
of trauma patients. It has been shown that trauma patients exhibit lower than normal
platelet contractility, and that severe trauma patients exhibit even lower platelet
contractility [49]. In the future, using our global and local aggregate contraction
measurements to study blood of trauma patients and its contractile ability may be able to
provide further insight into how or in what way blood from trauma patients is less
contractile than blood from healthy donors.
Lastly, I would like to further investigate, and potentially further optimize our
global and local aggregate measurements. In our experiments, we use 250 um x 250um
collagen patches to study clot contraction. However, in vivo, clot formation could vary in
size greatly. It would be interesting to see how global and local contraction compares to
each other based on clot size. In the future, we could pattern a collagen strip that is
thinner or wider, and/or utilize a microfluidic device with a thinner or wider channel
width, thereby allowing us to make collagen patches of varying sizes. It would also be
useful to further investigate ways of optimizing global and local contraction. For
example, the global aggregate contraction algorithm utilizes 5 lines drawn in the middle
portion of the clot (Supp. Fig. S3-2). However, we could look to include the middle 10,
20, 50, or 100 lines, for example, to see if this would improve the accuracy of contraction
measurements among different clots within the same condition (among the same donor
and among different donors).
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5.3

Further evaluation of anti-GPVI Fab E12 and the role of PS exposure in
propagating platelet deposition

Figure 5-2. Time-sequential inhibition of thrombin demonstrated varying anti-GPVI potency on
platelet deposition and fibrin deposition.
We perfused CTI-treated WB ±anti-GPVI (no annexin V) over collagen/TF for 15 minutes at an initial wall
shear rate of 100s-1, with a switch to PPACK-treated WB ±anti-GPVI at either 90s, 270s, or 540s. The
presence (or absence) of anti-GPVI remained consistent in each channel throughout the experiment, while
the switch changed each condition from CTI-treated WB to PPACK-treated WB. We added CD61
fluorophore to label for platelets (A), and fluorescent fibrinogen to label for fibrin (B). We measured
fluorescence intensity values for platelets (C) and fibrin (D) over the course of the experiment. (A.U. =
arbitrary units)
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There are a number of further experiments we could perform with anti-GPVI Fab
E12 to elucidate its effects on clot development. We showed that when anti-GPVI and
annexin V were added in combination from t=0s, there was significantly reduced platelet
deposition (Fig. 4-5); we also showed that when we added anti-GPVI at later times (t=30s
or 90s), normal platelet deposition still occurred. However, it would be useful to see how
inhibiting thrombin at different points in time may affect platelet deposition. We
performed a preliminary experiment where we ran CTI-treated WB ±anti-GPVI (no
annexin V) with a switch to PPACK-treated WB ±anti-GPVI at either 90s, 270s, or 540s
(Fig. 5-2). The presence (or absence) of anti-GPVI remained consistent in each channel
throughout the experiment, while the switched channels changed each condition from
CTI-treated WB to PPACK-treated WB. This allowed us to see how and when thrombin
affects the potency of anti-GPVI Fab on platelet deposition. In channels where there was
no switch, we observed little difference in platelet deposition between control and antiGPVI conditions (Fig. 5-2A, C), although there was a significant reduction in fibrin
polymerization in anti-GPVI channels (Fig. 5-2B, D), as previously shown in Figure 4-5.
In channels where there was a switch to PPACK-treated WB, the timing of the
switch seemed to play a significant role in affecting platelet deposition and fibrin
polymerization. Switching at 90s from CTI-treated WB to PPACK-treated WB resulted
in a limited and comparable fibrin polymerization for both control and anti-GPVI
conditions (Fig. 5-2B, D). However, the 90s switch significantly reduced platelet
deposition in anti-GPVI channels compared to control and compared to no switch anti80

GPVI (Fig. 5-2A, C). This showed that, in the presence of anti-GPVI, when thrombin
was no longer available to contribute to platelet activation, platelet deposition was
reduced. Additionally, in the 90s switch conditions, the control channel had higher
platelet FI by the end of the experiment compared to anti-GPVI. This demonstrated the
combination of anti-GPVI and thrombin inhibition significantly limited platelet
deposition. For switch channels at 270s or 540s, we saw a gradual decrease in fibrin
deposition after the switch in both control and anti-GPVI conditions, although fibrin was
greater in control compared to anti-GPVI at the switch. In terms of platelet deposition for
the 270s and 540s switch conditions, platelet deposition looked similar between control
and anti-GPVI up until the switch. After the switch, anti-GPVI channels had a gradual
(270s) or slight (540s) reduction in platelet FI compared to control. These results, when
considered with Figures 4-3 and 4-4, show the significance of thrombin in allowing for
fibrin formation and platelet deposition in the presence of anti-GPVI. Notably, when
thrombin was present from t=0s and anti-GPVI Fab was added at later time points, there
was little to no effect on platelet, fibrin, or annexin V FI (Fig. 4-3); when anti-GPVI was
present from t=0s and thrombin inhibitor was added at later times points, there was a
significant effect on platelet deposition and fibrin polymerization.

81

82

Figure 5-3. Time-sequential addition of annexin V in the presence of anti-GPVI had little effect on
platelet deposition or PS exposure, but a minimal effect on fibrin deposition.
We perfused CTI-treated WB ±anti-GPVI ±annexin V over collagen/TF for 15 minutes at an initial wall
shear rate of 100s-1, with a switch to +annexin V at either 30s, 90s, 270s, or 540s. The presence (or
absence) of anti-GPVI remained consistent in each channel throughout the experiment, while switch
channels went from +anti-GPVI -annexin V to +anti-GPVI +annexin V. We added CD61 fluorophore to
label for platelets (A), fluorescent fibrinogen to label for fibrin (B), and annexin V to label for PS exposure
(C). We measured fluorescence intensity values for platelets (D), fibrin (E), and annexin V (F) over the
course of the experiment. (A.U. = arbitrary units)

We showed in Figure 4-5 that when annexin V or anti-GPVI Fab were added
individually, they each had no significant effect on platelet deposition, but when added in
combination, they significantly limited platelet deposition. To further understand this
effect, it would be helpful to determine if the combination of annexin V and anti-GPVI
still has this limiting effect when one is added at a later time point. We investigated
adding anti-GPVI Fab at later time points with annexin V present from t=0s in Figure 43. Here, in preliminary results, we investigated adding annexin V at later time points with
anti-GPVI present from t=0s (Fig. 5-3). The left four channels mimicked conditions in
Fig. 4-5 (Fig. 5-3A, B, C), while the right four channels started with anti-GPVI Fab
present at t=0s, with annexin V added at either 30s, 90s, 270s, or 540s. We saw that when
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annexin V was added at later time points (after t=0s), platelet deposition was comparable
to control, annexin V alone, or anti-GPVI alone, while anti-GPVI + annexin V (t=0s)
showed reduced platelet deposition. In terms of fibrin, channels that added annexin V at
later times had slightly increased fibrin deposition; however, fibrin FI remained at or
below levels in anti-GPVI (no annexin V) channels. Fibrin FI for anti-GPVI + annexin V
(t=540s) was comparable to fibrin FI for anti-GPVI (no annexin V), while fibrin FI was
lower for anti-GPVI + annexin V (t=30s) and anti-GPVI + annexin V (t=0s), which were
similar in value. Annexin V levels for switch channels were much closer to anti-GPVI +
annexin V (t=0s) channels than to annexin V (no anti-GPVI) channels, regardless of
switch time. Annexin V levels were slightly higher for switch channels compared to antiGPVI + annexin V (t=0s), likely because background subtraction of initial, t=0s images
did not have annexin V fluorophore in the switch channels; thus the slight increase in
annexin V levels in switch channels (compared to anti-GPVI + annexin V @ t=0s), while
minimal, was likely due from background noise.
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Figure 5-4. Annexin V has a slight inhibitory effect on fibrin deposition.
We perfused CTI-treated WB ± a switch to annexin V at either 90s, 270s, or 540s over collagen/TF at an
initial wall shear rate of 100s-1. We added CD61 fluorophore to label for platelets (A), fluorescent
fibrinogen to label for fibrin (C), and annexin V to label for PS exposure (E). We measured fluorescence
intensity values for platelets (B), fibrin (D), and annexin V (F) over the course of the experiment. (A.U. =
arbitrary units)

Lastly, we demonstrated in Chapter 2 (Supplemental Fig. S2-1) that annexin V has
a slight inhibitory effect on fibrin. While we believe this was likely because PS was
blocked by annexin V to prevent further propagation of thrombin and subsequent fibrin
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polymerization, it would be helpful to further elucidate why and how this occurred. In a
preliminary study, we looked at adding annexin V to CTI-treated WB at different time
points to see if or how annexin V affects fibrin polymerization throughout the experiment
(Fig. 5-4). We perfused CTI-treated WB ± switch to annexin V at 90s, 270s, or 540s over
collagen/TF at an initial wall shear rate of 100s-1. We had a control channel with annexin
V from t=0s (no switch). Across all conditions, we observed no significant differences in
platelet deposition (Fig. 5-4A, B). In terms of fibrin polymerization, there were slight
deviations between each condition, with annexin V @ t=0s and annexin V @ t=90s
having the lowest values, followed by annexin V @ t=270s, and finally annexin V @
t=540s had the highest fibrin FI. This was in agreement with our earlier results (Supp.
Fig. S2-1), but expanded upon the results to show that annexin V can still have slight,
albeit observable, effects on fibrin polymerization when added after t=0s. Lastly, as
expected, annexin V FI values varied greatly between different conditions, since this was
entirely dependent on when annexin V was added to different channels.
We have described a handful of experiments here that aim to further clarify the
effect of anti-GPVI Fab (especially in combination with annexin V) on platelet
deposition, fibrin polymerization, and PS exposure. However, further research, both in
our microfluidic device described here, as well as other experimental designs, should be
considered to better our understanding of this anti-GPVI Fab E12.
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APPENDICES
Appendix A: Chapter 2
Supplemental Methods
Reagents and Materials
The following reagents were obtained and kept at the appropriate conditions in
accordance with the vendor’s instructions: corn trypsin inhibitor (CTI), Phe-Pro-Argchloromethylketone (PPACK), H-Gly-Pro-Arg-Pro-OH (GPRP; EMD Millipore,
Burlington, MA), recombinant human tissue plasminogen activator (tPA; Abcam,
Cambridge, MA), Sigmacote (Sigma, St. Louis, MO), type I fibrillar collagen (Chronolog, Havertown, PA), tissue factor (TF; Siemens, Malvern, PA). Fluorophores included
anti-human CD61 antibody (BD Biosciences, San Jose, CA), AF647 human fibrinogen
(Haematologic Technologies, Essex Junction, VT), AF488-conjugated annexin V
monoclonal antibody (Thermo Fischer, Waltham, MA).
Blood collection
Blood donors were self-reported as medication-free for at least 7 days prior to blood
collection. All blood draws were done with the use of a high concentration of CTI (40
µg/ml) to ensure inhibition of contact pathway-induced coagulation. All donors
consented in accordance with the University of Pennsylvania Institutional Review Board
and the declaration of Helsinki. Fluorophores were added as needed in the following
concentrations: anti-CD61 antibody (1:50 v/v dilution), AF647 fibrinogen (1:80 v/v
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dilution), AF488 annexin V (1:80 v/v dilution). Additional reagents were added as
needed in the following concentrations: PPACK (10 mM stock solution, 1:100 v/v
dilution), GPRP (100 mM stock, 1:20 v/v dilution), tPA (1.3 mg/ml stock solution; 30
nM final concentration).
Preparation of collagen/TF on glass slide
Glass slides were first rinsed with ethanol, then dried using filtered air. Sigmacote was
then added to glass slides; slides were then rinsed with deionized water and dried. A
patterning device was vacuum-sealed to the glass slide. For slides without TF, 5 µL of
collagen was perfused through the patterning device; 20 µL of 0.5% Bovine Serum
Albumin (BSA) was then placed on top of both the inlet and outlet ports to incubate for
30 minutes. For slides with TF, 5 µL of collagen was perfused through the patterning
device, 5 µL of TF was then perfused through the patterning device, then 20 µL of 0.5%
BSA was placed on top of both the inlet and outlet ports to incubate for 30 minutes. After
30 minutes, BSA at the outlet was removed, and the remaining BSA at the inlet port was
perfused through the patterning device. Patterning devices were removed, leaving a 250µm wide collagen (±TF) strip.
Fluorescence Intensity vs. time
In order to show fluorescence intensity (FI) of fluorophores (CD61, fluorescent
fibrinogen, or annexin V) over time, images of each clot were uploaded and compiled
into a time sequence (stack) in ImageJ. The initial image (at t = 0s) was subtracted from
the stack of images to subtract any background fluorescence. A rectangular area
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(approximately 2/3 of the central area of the clot) was used to calculate FI in the stack for
each fluorophore in each clot. FI values were then exported to Matlab where plots were
made with FI values vs. time. Plots were made as average ± standard deviation for FI
values over time.
Autocorrelation metric calculations for PS spatial sorting
We first input a 150 µm x 150 µm image (corresponding to a 233 x 233 matrix of pixel
values) of the final (15-minute) annexin V FI for each condition into Matlab. This matrix
of pixel values was then converted to a zero-mean matrix of pixel values by subtracting
the matrix average from each matrix element. This was done in order to maximize the
values of high fluorescence overlay and low fluorescence overlay between the matrices.
This matrix was used to calculate the autocorrelation matrix, which was then truncated
and summed to yield an autocorrelation metric.
Pearson correlation coefficient calculations for PS temporal sorting
Images at 9 minutes and 15 minutes for a particular clot were taken at the same size (150
µm x 150 µm), so both matrices were the same size in Matlab and corresponded to the
same location in space in the clot. The 15-minute images were the same images used in
the autocorrelation metric calculations.
Statistical Analyses
Statistical differences with p-values between conditions were calculated using unpaired
Welch’s t-tests in GraphPad (ns signifies p > 0.05).
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Supplementary Results
We investigated the role of platelet integrin αIIbβ3 on PS sorting. We inhibited αIIbβ3 with
GR-144053 (GR). We perfused high CTI WB + GR over collagen or collagen/TF. The
GR prevented secondary platelet deposition as expected, resulting in a sparse monolayer
of platelets bound directly to the collagen. In the presence of TF, we observed fibrin
formation in the presence or absence of GR. However, we observed relatively little PS
sorting in the +GR condition, regardless of the presence of absence of fibrin. This was
expected since the platelets were sparse and unable to make sufficient platelet-platelet
contacts and adherent platelets were firmly bound to collagen.
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Supplemental Figures

Supplemental Figure S2-1. Annexin V has a slight inhibitory effect on fibrin formation.
High CTI WB was perfused with and without annexin V over collagen/TF at an initial shear rate of 100s-1.
CD61 and fluorescent fibrinogen were both added to label platelets and fibrin, respectively. Images of clots
were taken in 90-second intervals for 15 minutes; example images are illustrated at 3 minutes (A), 7.5
minutes (B), and 15 minutes (C). The fluorescence intensities for CD61 (D) and fluorescent fibrinogen (E)
were measured over time. Graphs illustrate the average ± standard deviation for 3 different donors (N=3)
and 21 individual clots (n=21).
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Supplemental Figure S2-2. Illustration of example contraction measurements.
Contraction was measured as % change in clot length between 9- and 15-minute images of annexin V
fluorescence.
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Supplemental Figure S2-3. Illustration of example full autocorrelation matrix and truncated
autocorrelation matrix.
Autocorrelation matrices were calculated using “xcorr2” function in Matlab from 150 x 150 µm clots (233
x 233 pixels). The autocorrelation matrix output was (2n-1) x (2n-1) for an n x n input image; in the case of
a 233 x 233 pixel input image, the autocorrelation matrix dimensions were 465 x 465. The autocorrelation
matrix was then truncated by 20 pixels from the center of the autocorrelation matrix (233, 233) in each
direction, corresponding to a 41 x 41 truncated matrix. The summation of this matrix was the
autocorrelation metric, corresponding to the degree to which an image correlates with itself.
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Supplemental Figure S2-4. Illustration of example PS spatial sorting measurements.
PS spatial sorting was measured using an autocorrelation metric to evaluate the final annexin V FI of each
clot. Synthetic and real examples illustrate that as images become less sorted and more mixed, the
autocorrelation metric decreases. Images of clots used were 150 µm x 150 µm areas of the central portion
of a clot.
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Supplemental Figure S2-5. Illustration of example PS temporal sorting measurements.
PS temporal sorting was measured using a Pearson correlation coefficient between 9- and 15-minute
annexin V images within a clot. Synthetic and real examples illustrate that the similarity of distribution
between the images correlates with the Pearson correlation coefficient. Images of clots used were 150 µm x
150 µm areas of the central portion of a clot.
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Supplemental Figure S2-6. Average fluorescence intensities over time for high CTI WB ± PPACK
perfused over collagen/TF.
Fluorescence intensities for CD61 (A) and fluorescent fibrinogen (B) over time. Graphs illustrate the
average ± standard deviation for 4 donors (N = 4) and 28 individual clots (n = 28).

Supplemental Figure S2-7. Average fluorescence intensities over time for high CTI WB ± GPRP
perfused over collagen/TF.
Fluorescence intensities for CD61 (A) and fluorescent fibrinogen (B) over time. Graphs illustrate the
average ± standard deviation for 3 donors (N = 3) and 21 individual clots (n = 21).
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Supplemental Figure S2-8. Average fluorescence intensities over time for high CTI WB ± tPA
perfused over collagen/TF.
Fluorescence intensities for CD61 (A) and fluorescent fibrinogen (B) over time. Graphs illustrate the
average ± standard deviation for 3 donors (N = 3) and 22 individual clots (n = 22).

Supplemental Figure S2-9. Average fluorescence intensities over time for high CTI WB ± PPACK
perfused over collagen (no TF).
Fluorescence intensities for CD61 (A) and fluorescent fibrinogen (B) over time. Graphs illustrate the
average ± standard deviation for 3 donors (N = 3) and 20 individual clots (n = 20).
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Supplemental Figure S2-10. Autocorrelation metric at 6 and 15 minutes.
Autocorrelation metric values were calculated and compared for 6- and 15-minute images for (A) ±PPACK
over collagen/TF, (B) ±GPRP, (C) ±tPA, and (D) ±PPACK over collagen (no TF).
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Appendix B: Chapter 3

Supplemental Figure S3-1. Explanation of image thresholding process.
Images (for both platelets and P-selectin fluorescence) were made binary in Matlab for contraction analysis.
The threshold value for binary images was 1/2 of the mean fluorescence of each image. This threshold
value was used consistently across all images. Once binarized, clots were analyzed for global and local
contraction.
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Supplemental Figure S3-2. Example global contraction measurement.
Once images were binary, measurements were made at 5 different points in the x direction of each clot: at
the central pixel, ± 25 pixels, and ± 50 pixels. These measurements were then averaged and used to
calculate the global % contraction for the clot.

Supplemental Figure S3-3. Example local contraction measurement.
Once images were binary, the % of the clot area covered by platelets (white) was calculated in Matlab for
each image of a clot (at 7.5 and 15 min). The % area coverage for each image was used to calculate the
local % contraction for the clot.
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Supplemental Figure S3-4. Global and local aggregate contraction changes for CD61 and P-selectin
over time.
Starting at 7.5 min, global and local contraction was measured every 90s for CD61 and P-selectin images.
The graphs correspond to the clot length or area coverage at different time points relative to 7.5 min. This
was done for global CD61 contraction (A), local CD61 contraction (B), global P-selectin contraction (C),
and local P-selectin contraction (D).
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Appendix C: Chapter 4

Supplemental Figure S4-1. Comparison of Epifluorescence and Confocal Images.
High CTI WB was perfused over collagen/TF for 7.5 min, with images taken using the epifluorescence
microscope at 7.5 min (A). Then clots were fixed, as described in Methods, and taken to image using the
confocal microscope (B). Representative confocal images are from 12.05 µm above the collagen surface.
Images include individual fluorophores for platelets, fibrin, and annexin V, as well as an overlay of all
three.
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Supplemental Figure S4-2. Confocal images at different heights in the z-direction.
Images from the same clot in Supp. Fig. S4-1 were taken at different heights in the z-direction, starting at
the glass surface (0 µm) up to 57.84 µm above the glass surface. Images for overlay (A), platelets (B),
fibrin (C), and annexin V (D) are included.
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Supplemental Figure S4-3. Quantitative analysis of confocal images at different heights in the zdirection.
Images from the same clot in Supp. Fig. S4-2 were quantitatively analyzed for the fluorescence intensity
for platelets (blue), fibrin (orange), and annexin V (grey) at different heights in the z-direction (A).
Fluorescence values in each data set in (A) were divided by the respective maximum value in each
individual data set to yield a normalized fluorescence intensity among the different fluorophore labels (B).
(A.U.= arbitrary units)

104

Supplemental Figure S4-4. P-selectin staining of platelets treated with GR-144053.
High CTI WB with or without GR-144053 was perfused over collagen/TF at 100s-1 for 15 minutes. CD61,
fluorescent fibrinogen, and P-selectin fluorophores were added to label platelets (A), fibrin (B), and alphagranule release (C), respectively, with images taken at 270s and 630s. Fluorescence intensities for platelets
(D), fibrin (E), and P-selectin (F) were measured throughout the course of the experiments. Representative
data are from 1 individual donor (N = 1) and 8 individual clots (n = 8). (A.U. = arbitrary units)
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Supplemental Figure S4-5. With thrombin inhibited, anti-GPVI strongly inhibits platelet deposition
regardless of annexin V presence.
PPACK-treated WB, with and without annexin V and anti-GPVI, was perfused over collagen at 100s-1 with
CD61, fluorescent fibrinogen, and annexin V fluorophores added for platelets (A), fibrin (C), and annexin
V (E). Fluorophores were measured throughout the course of the experiment for platelet fluorescence (B),
fibrin fluorescence (D), and annexin V fluorescence (F). Representative data are from 1 individual donor
(N = 1) and 4 individual clots (n = 4). (A.U. = arbitrary units).
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